Review

Insight into the Development of PET Radiopharmaceuticals for Oncology

Joseph Lau 1, Etienne Rousseau 2, Daniel Kwon 3, Kuo-Shyan Lin 3, François Bénard 3 and Xiaoyuan Chen 1,*

1 Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD 20892, USA; lauj2@nih.gov
2 Department of Nuclear Medicine and Radiobiology, University of Sherbrooke, Sherbrooke, QC J1H 5N4, Canada; etienne.rousseau@usherbrooke.ca
3 Department of Molecular Oncology, BC Cancer, Vancouver, BC V5Z 1L3, Canada; dkwon@bccrc.ca (D.K.); klin@bccrc.ca (K.-S.L.); fbenard@bccrc.ca (F.B.)
* Correspondence: shawn.chen@nih.gov; Tel.: +1-301-451-4246

Received: 28 April 2020; Accepted: 18 May 2020; Published: 21 May 2020

Abstract: While the development of positron emission tomography (PET) radiopharmaceuticals closely follows that of traditional drug development, there are several key considerations in the chemical and radiochemical synthesis, preclinical assessment, and clinical translation of PET radiotracers. As such, we outline the fundamentals of radiotracer design, with respect to the selection of an appropriate pharmacophore. These concepts will be reinforced by exemplary cases of PET radiotracer development, both with respect to their preclinical and clinical evaluation. We also provide a guideline for the proper selection of a radionuclide and the appropriate labeling strategy to access a tracer with optimal imaging qualities. Finally, we summarize the methodology of their evaluation in vitro and animal models and the road to clinical translation. This review is intended to be a primer for newcomers to the field and give insight into the workflow of developing radiopharmaceuticals.

Keywords: positron emission tomography; diagnostic imaging; radiopharmaceuticals; radiochemistry; personalized medicine

1. Introduction

Positron emission tomography (PET) is a noninvasive nuclear imaging modality that is used, amongst many indications, for diagnosis, staging, and treatment monitoring of cancer [1]. PET imaging is performed by administering, usually intravenously, a positron-tagged radiopharmaceutical into a patient [2]. As the radionuclide decays, emitted positrons travel a short distance before interacting with nearby electrons [2]. The interaction between a positron and an electron leads to an annihilation event, emitting two 511 keV photons in opposite directions [2]. The photons are detected in coincidence, and the signals are reconstructed using computer algorithms to generate 2D projections or 3D images [2]. Widely considered as the most sensitive imaging modality, PET can yield quantitative information such as activity per tissue volume (kBq/mL) versus time or standardized uptake values (SUV), which are more widely used in clinic [3].

The majority of PET scans are performed using [18F]fluorodeoxyglucose ([18F]FDG), the gold standard of PET radiopharmaceuticals. Leveraging the Warburg effect [4], [18F]FDG is taken up by cancer cells with enhanced metabolic and glycolytic rates. However, the uptake of [18F]FDG is not cancer specific [5], lowering the specificity of imaging, and also, some cancers have low avidity for glucose as an energy source. Because of this, there is a niche for the development of alternative imaging probes. Furthermore, as radioligand therapy (RLT) continues to cement itself as a prominent treatment
strategy [6], PET radiopharmaceuticals can assess drug-target expression across lesions in real time and identify potential responders.

In this review, we discuss the process of developing PET radiopharmaceuticals, focusing on candidate selection, radiochemistry, and preclinical evaluation with the goal of translation. We also briefly summarize essential guidelines by regulatory bodies for preclinical assay of diagnostic radiopharmaceuticals to be performed before clinical trials. We hope this will serve as a resource for the nuclear medicine community and help expedite the progression of radiopharmaceuticals into clinical trials to improve patient care.

2. Targeting Vectors

A PET radiopharmaceutical is a pharmacophore that is labeled with a positron-emitting radionuclide. Pharmacophores include, but are not limited to, small molecules, aptamers, amino acids, peptides, antibodies, antibody mimetics, and nanoparticles. These molecules can target cancer biomarkers (e.g., enzymes, receptors, and transporters) or biological processes (e.g., energy metabolism, hypoxia, acidosis, and oxidative stress). The imaging of different cell populations within the tumor microenvironment like cancer-associated fibroblasts and immune cells has also emerged as an area of increased interest. Table 1 provides examples of PET radiopharmaceuticals that have been evaluated in the clinic for various indications. Although these molecules differ in composition, they generally share the following attributes as imaging agents [7]:

**High specificity:** The minimization of off-target binding ensures that sites of uptake are truly representative of the molecular pathology and not of a physiological process. It is not uncommon for small molecule inhibitors to bind promiscuously to other related proteins (e.g., pan-kinase inhibitors [8,9]).

**High binding affinity:** Radiopharmaceuticals should bind with nano- or subnanomolar binding affinity to their target of interest ($K_d < 50$ nM). This increases the sensitivity for receptors/targets that are expressed at low densities and are readily saturable.

**Rapid clearance from nontarget tissues:** PET radiopharmaceuticals clear through the renal pathway, hepatobiliary pathway, or both. The route of elimination depends on multiple factors including size, lipophilicity, charge, and plasma-protein binding. When there is sustained tumor uptake, imaging contrast improves with progressive clearance from blood (Figure 1). In addition, the rapid excretion of radiopharmaceuticals reduces radiation exposure to patients.

**Stability in vivo:** Following administration, radiopharmaceuticals circulate before reaching tumor site(s). The uptake period of a radiopharmaceutical may range from hours (e.g., peptides) to days (e.g., antibodies); therefore, stability against enzymes in plasma or on target tissues is needed. Notably, radiopharmaceuticals that rely on metabolic trapping as a mechanism for retention will not be wholly stable.

**Low immunogenicity or toxicity:** Administered at microdoses, radiopharmaceuticals are unlikely to induce pharmacological or allergic effects. However, the potential for adverse events must still be carefully assessed as some agents will be used multiple times for response monitoring [10].

**Accessible and cost effective:** PET radiopharmaceuticals, including their radiolabeling precursors, should be readily available at low costs and allow for routine clinical use.

Although not a generalizable property, another important consideration in design of PET probes is organ specificity. In many cases, well-differentiated cancers have phenotypes closely related to their organ of origin and designing radiotracers that target normal physiological pathways of those tissues to image in situ or metastatic neoplasia is an attractive strategy. A radiopharmaceutical leveraging this strategy is Na$^{+}$/I$^-$ symporter [11]. Another example is $[^{18}\text{F}]$FDGal, targeting the galactose pathway in liver [12]. $[^{18}\text{F}]$FDGal can differentiate well-differentiated hepatocellular carcinoma from lesions of other cancers metastatic to liver because $[^{18}\text{F}]$FDGal accumulates more readily in hepatocarcinoma. In these cases, organ specificity translates in tumor type specificity, in opposition to general-purpose tracers like $[^{18}\text{F}]$FDG that image many types of cancers without allowing easy differentiation between their origin [5].
Table 1. Representative positron emission tomography (PET) radiopharmaceuticals evaluated in clinical studies for oncology.

| Biological Process/Target | Radiopharmaceutical | Vector | Indication | References |
|---------------------------|----------------------|--------|------------|------------|
| A33                       | $^{124}$I-I-huA33     | Antibody | Colorectal cancer | [13]       |
| Acetyl-CoA synthetase     | $^{[1]C}$acetate §  | Salt    | General cancers | [14]       |
| Amino acid transport      | $^{[1]}$C)methionine # | Amino acid | Glioma, neuroendocrine tumors, prostate cancer | [15–23]   |
| Androgen receptor (AR)    | $^{[1]}$F]FDHT       | Hormone | Prostate cancer | [24,25]    |
| Apoptosis                 | $^{[1]}$F]ML-10      | Small molecule | Glioblastoma multiforme, breast cancer, lung cancer | [26,27]    |
| Bone remodeling           | $^{[1]}$F]NaF *,#    | Salt    | Osseous lesions | [28]       |
| CA19.9                    | $^{[89]}$Zr-Zr-DFO-HuMab-SB1 | Antibody | Pancreatic cancer and bladder cancer | [29]       |
| Carbonic anhydrase 9 (CA-IX) | $^{[124]}$I-girentuximab | Antibody | Clear-cell renal cell carcinoma | [30–32]   |
| Carcinoembryonic antigen (CEA) | $^{[68]}$Zr-Zr-AMG 211 | Bispecific T-cell engager | Gastrointestinal adenocarcinoma | [33]       |
| CD8                       | $^{[89]}$Zr-Zr-Df-IC522M2C | Minibody | Melanoma, lung cancer, hepatocarcinoma | [34]       |
| CD20                      | $^{[89]}$Zr-Zr-rituximab | Antibody | B cell lymphoma | [35,36]    |
| CD44v6                    | $^{[89]}$Zr-Zr-U36    | Antibody | Head and neck cancer | [37]       |
| C-X-C chemokine receptor type 4 (CXCR4) | $^{[64]}$Cu-Cu-plerixafor | Small molecule | Hematological and solid malignancies | [38–40]    |
| Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) | $^{[89]}$Zr-Zr-ipilimumab | Antibody | Melanoma | [41]       |
| Epidermal growth factor receptor (EGFR) | $^{[1]}$C)trastuzumab | Small molecule | Nonsmall cell lung carcinoma; colorectal cancer | [42–46]    |
| Epidermal growth factor receptor 2 (ERBB2) | $^{[89]}$Zr-Zr-neratinib | Antibody |       |           |
| Epidermal growth factor receptor 3 (ERBB3) | $^{[89]}$Zr-Zr-trastuzumab | Antibody | Solid malignancies | [50,51]    |
| Estrogen receptor (ER)    | $^{[1]}$F]FES$^{[18]}$F]FMFES | Hormone | Breast cancer and gynecologic cancers | [52]       |
| Fibroblast activation protein α | $^{[68]}$Ga-Ga-FAP-04 | Small molecule | Solid malignancies | [53–55]    |
| Galactose metabolism      | $^{[1]}$F]FDGal      | Small molecule | Hepatocarcinoma | [56]       |
| Biological Process/Target | Radiopharmaceutical | Vector | Indication | References |
|--------------------------|---------------------|--------|------------|------------|
| Gastrin-releasing peptide receptor (GRPR) | $^{64}$Cu[Cu-CB-TE2A-AR06] | Peptide | Prostate cancer, breast cancer, glioma | [57–65] |
| | $^{18}$F-BAY 864367 | | | |
| | $^{68}$GaGa-RM2 | | | |
| | $^{68}$GaGa-SB3 | | | |
| | $^{68}$GaGa-RM26 | | | |
| | $^{68}$GaGa-BBN-RGD | | | |
| | $^{68}$GaGa-NOTA-Aca-BBN | | | |
| | $^{68}$GaGa-NeoBOMB1 | | | |
| Glucagon-like peptide 1 receptor (GLP-1R) | $^{68}$Ga-NOTA-exendin-4 | Peptide | Insulinoma | [66] |
| Glucose metabolism | $^{18}$F]FDG | Small molecule | Neoplasm | [1] |
| Glypican 3 | $^{124}$I-codrituzumab | Antibody | Hepatocarcinoma | [67] |
| | | | | |
| Hypoxia | $^{18}$F]FAZA | | | |
| | $^{18}$F]FMISO | | | |
| | $^{18}$F]FAZA | | | |
| | $^{18}$F]HX4 | | | |
| | $^{68}$Ga-Cu-ATSM | | | |
| Integrin $\alpha_4\beta_1$ | $^{64}$Cu[LLP2A | Peptidomimetic | Multiple myeloma | [74] |
| Integrin $\alpha_4\beta_3$ | $^{18}$F]Galacto-RGD | Peptide | Solid malignancies | [75–82] |
| | $^{18}$F]PP(CRGD)$_2$ | | | |
| | $^{18}$F-flucilatide | | | |
| | All$^{18}$F]afa胎胎胎胎-I | | | |
| | All$^{18}$F]afa胎胎胎胎-II | | | |
| | $^{68}$GaGa-NOTA-PRGD2 | | | |
| Integrin $\alpha_v\beta_6$ | $^{11}$C]choline | Small molecule | Pancreatic ductal adenocarcinoma and ovarian cancer | [67] |
| | $^{18}$F]PSMA-1007 | | | |
| | $^{18}$F]DCFPyL | | | |
| | $^{18}$F]DCBHiC | | | |
| | $^{68}$GaGa-P5MMA-7 | | | |
| | | | | |
| | Poly(ADP-ribose) polymerase 1 (PARP1) | | | |
| | $^{68}$GaGa-DOTA-GGNle-CycMSH$_{hex}$ | Peptide | Melanoma | [86] |
| | | | | |
| Neurokinin 1 receptor (NK1R) | $^{68}$GaGa-DOTA-SP | Peptide | Glioma | [88] |
| Neurotensin 1 receptor (NTS1R) | All$^{18}$F]NOTA-neurotensin | Peptide | Prostate cancer | [89] |
| Phospholipid synthesis | $^{11}$C]choline | Salt | Prostate cancer | [90,91] |
| | $^{18}$F]choline | | | |
| Poly(ADP-ribose) polymerase 1 (PARP1) | $^{[18}$F]PARPi | Small molecule | Head and neck cancer | [92] |
| Prostate-specific membrane antigen (PSMA) | $^{99}$Zr$^{99}$Zr-[Huf]| Antibody | Prostate cancer | [93–98] |
| | $^{18}$F]PSMA-1007 | | | |
| | $^{18}$F]DCFPyL | | | |
| | $^{18}$F]DCBHiC | | | |
| | $^{68}$GaGa-P5MMA-7 | | | |
| | $^{68}$GaGa-P5MMA-11 | | | |
| | $^{68}$GaGa-P5MMA-617 | | | |
| | | | | |
| | $^{99}$Zr$^{99}$Zr-[Huf]| Antibody | Prostate cancer | [99,100] |
| | $^{18}$F]PSMA-1007 | | | |
| | $^{18}$F]DCFPyL | | | |
| | $^{18}$F]DCBHiC | | | |
| | $^{68}$GaGa-P5MMA-7 | | | |
| | $^{68}$GaGa-P5MMA-11 | | | |
| | $^{68}$GaGa-P5MMA-617 | | | |
| | | | | |
| | Programmed cell death protein (PD-1) | $^{99}$Zr$^{99}$Zr-durvalumab | Antibody | Non-small cell lung carcinoma | [99,100] |
| | $^{99}$Zr$^{99}$Zr-nivolumab | | | |
| | $^{99}$Zr$^{99}$Zr-pembrolizumab | | | |
| | Programmed death-ligand 1 (PD-L1) | $^{[18}$F]BMS-986192 | Adnectin | Non-small cell lung carcinoma, bladder cancer, breast cancer | [100–102] |
| | $^{99}$Zr$^{99}$Zr-atezolizumab | Antibody | Non-small cell lung carcinoma | [100–102] |
| | | | | |
| Six-transmembrane epithelial antigen of prostate-1 (STEAP1) | $^{99}$Zr$^{99}$Zr-DFO-MSTP2109A | Antibody | Prostate cancer | [103] |
Table 1. Cont.

| Biological Process/Target | Radiopharmaceutical | Vector | Indication | References |
|---------------------------|----------------------|--------|------------|------------|
| Sodium/iodine transporter | Na$^{[24]}$I Salt | Thyroid cancer | [104] |
| Somatostatin receptor 2 (SSTR2) | $[^{64}]$Cu$[^{64}]$Cu-SARTATE * | Peptide | Neuroendocrine tumors | [105–108] |
| | $[^{68}]$Ga$[^{68}]$Ga-DOTA-TATE * | | | |
| | $[^{68}]$Ga$[^{68}]$Ga-DOTA-TOC * | | | |
| | $[^{68}]$Ga$[^{68}]$Ga-DOTA-NOC | | | |
| | $[^{68}]$Ga$[^{68}]$Ga-NODAGA-JR11 | | | |
| Thymidine kinase (DNA replication) | $[^{18}]$F$[^{18}]$FLT # | Nucleoside | Solid malignancies | [109] |
| Transforming growth factor-beta (TGF-β) | $[^{89}]$Zr$[^{89}]$Zr-fresolimumab Antibody | Glioma | [110] |
| Vascular endothelial growth factor receptor (VEGFR) | $[^{89}]$Zr$[^{89}]$Zr-bevacizumab Antibody | Solid malignancies | [111–113] |

* Approved by the US Food and Drug Administration (FDA); # Approved by the European Medicines Agency (EMA).

Figure 1. Immuno-positron emission tomography (immuno-PET) imaging of prostate cancer with $[^{89}]$Zr$[^{89}]$Zr-11B6. (a) Coronal projection images in mice bearing LNCaP tumor xenograft. Longitudinal imaging shows continued uptake in tumor (T) with progressive clearance from liver (L). (b) Ex vivo biodistribution of activity in tumor and normal organs at 320 h.p.i. (c) Time-activity curves in %IA/g of tumors (squares) and blood (circles) for different doses of antibody. (d) Greater uptake observed in human kallikrein 2 producing VCaP model compared to LnCaP and nonproducing DU145 xenografts, indicating specificity. Uptake can also be blocked with excess antibody. Figure reproduced with permission from *Sci. Transl. Med.* 2016, 8(367): 367ra167 [114].
2.1. Probes Based on Bioactive Molecules

Biomimicry is a well-established method for drug discovery and development. Many radiopharmaceuticals are based on nutritional building blocks that sustain life (i.e., carbohydrates, amino acids, fatty acids, and nucleic acids; Figure 2). [$^{18}$F]FDG, regarded as the “molecule of the 20th century”, images the deregulation of cellular energetics—a hallmark of cancers [115]. [$^{18}$F]FDG was conceptualized in the early 1970s by researchers at the National Institutes of Health and the University of Pennsylvania [116,117] and its synthesis was described in 1978 by Ido and colleagues at the Brookhaven National Laboratory [118]. Initially applied for neuroimaging, [$^{18}$F]FDG was quickly adopted in oncology. As a glucose analog, [$^{18}$F]FDG is taken up by cells via glucose transporters and phosphorylated by hexokinase-2 for trapping and retention. The major limitation of [$^{18}$F]FDG is that it is not specific for cancer, as [$^{18}$F]FDG uptake is observed in other inflammatory/infectious diseases [5].

Radiolabeled amino acids (AAs) represent one of the larger classes of PET radiopharmaceuticals based on endogenous molecules. Radiolabeled AAs are typically labeled with $^{11}$C or $^{18}$F, and are used in the clinic to image pathologies like brain cancer, prostate cancer, breast cancer, and neuroendocrine tumors [16]. In particular, they are useful for glioma imaging, because they have lower background uptake in the brain compared to [$^{18}$F]FDG [119]. These radiopharmaceuticals are recognized and transported into cells by various AA transporters. Examples of radiolabeled AAs include but are not limited to [$^{11}$C]methionine, L-6-[18F]fluoro-3,4-dihydroxyphenylalanine ([18F]FDOPA), 2-[18F]fluoroethyl-tyrosine ([18F]FET), and anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid ([18F]FACBC). For [11C]-labeled AAs, the chemical structures are usually unmodified. For [18F]-labeled AAs, modifications at the AA side chain are common for labeling. Recently, Liu et al. reported a series of [18F]-labeled AAs by replacing the carboxylate group (−COO$^-$) with an isosteric trifluoroborate (BF$_3^-$) group that can be radiolabeled through an isotope exchange reaction [120]. This approach creates a framework for the development of AA radiopharmaceuticals that are analogous to their cannalnic counterparts (Figure 3). Furthermore, Britton and coworkers developed a method for the electrophilic radiofluorination of unactivated C–H bonds in hydrophobic amino acids (Figure 3) to produce [18F]-labeled AAs that can visualize glioblastoma and prostate adenocarcinoma xenografts [121,122].

Beyond [$^{18}$F]FDG and radiolabeled AAs, other biomimetic molecules also serve as templates for PET radiopharmaceuticals. [$^{18}$F]Fluorothymidine ([18F]FLT), a thymidine analog used to assess tumor proliferation is an example [109]. [$^{18}$F]FLT enters cancer cells via nucleoside transporters for pyrimidine salvage. Once inside the cell, [$^{18}$F]FLT is phosphorylated by thymidine kinase-1 and trapped. [$^{18}$F]FLT has been used to predict response to chemotherapy or radiotherapy in lung, breast, and prostate cancer. [$^{11}$C]Choline is another radiopharmaceutical that is readily taken up by cancers during proliferation. Choline can be converted into phospholipids for cell membrane synthesis. [$^{11}$C]Choline is indicated for patients with suspected prostate cancer recurrence upon elevated blood prostate-specific antigen (PSA) levels following initial therapy and noninformative scintigraphy, computed tomography, or magnetic resonance imaging [90]. Lastly, [$^{18}$F]Fluorodihtestosterone ([18F]FDHT) and [$^{18}$F]fluoroestradiol ([18F]F-FES) represent steroid derivatives that target androgen and estrogen receptors, respectively. They can be used to guide and assess antihormone therapies [24,25,52].

![Figure 2. Examples of PET radiopharmaceuticals based on bioactive molecules.](image-url)
The endogenous regulatory peptide is often taken as the lead sequence for development; it is iteratively appended at either the N- or C-terminus of the peptide, with some exceptions (e.g., neuropeptide Y receptor can be introduced to help stabilize the peptide. The radioprosthetic group is generally appended to identify the minimal sequence required for activity; essential AAs are determined by alanine scanning. Since regulatory peptides are prone to enzymatic degradation, modifications (e.g., D-amino acids, unnatural amino acids, backbone methylation, reduced amine bonds, cyclization) can be introduced to help stabilize the peptide. The radioprosthetic group is generally appended at either the N- or C-terminus of the peptide, with some exceptions (e.g., neuropeptide Y receptor radiopharmaceuticals). The particular success of SSTR2 imaging for neuroendocrine tumors (NETs) serves as the impetus for peptide receptor radionuclide therapy (PRRT) and radiotheranostics (Figure 4).

Peptidic or peptidomimetic ligands are among the most diverse groups of radiopharmaceuticals. Many neoplasms overexpress protein receptors that mediate biological processes like proliferation, hormone secretion, angiogenesis, and even metastasis [123–125]. The somatostatin receptor type 2 (SSTR2), gastrin-releasing peptide receptor, neurokinin-1 receptor, and cholecystokinin 2 receptor are a few examples of G protein-coupled receptors (GPCRs) that are targets for molecular imaging. The endogenous regulatory peptide is often taken as the lead sequence for development; it is iteratively truncated to identify the minimal sequence required for activity; essential AAs are determined by alanine scanning. Since regulatory peptides are prone to enzymatic degradation, modifications (e.g., D-amino acids, unnatural amino acids, backbone methylation, reduced amine bonds, cyclization) can be introduced to help stabilize the peptide. The radioprosthetic group is generally appended at either the N- or C-terminus of the peptide, with some exceptions (e.g., neuropeptide Y receptor radiopharmaceuticals [127]). The particular success of SSTR2 imaging for neuroendocrine tumors (NETs) serves as the impetus for peptide receptor radionuclide therapy (PRRT) and radiotheranostics (Figure 4).

Figure 3. Examples of 18F-labeled amino acid derivatives. (a) Representative structures of natural amino acids and the synthetic boramino acid variants. (b) In vivo PET projection images of [18F]FDG and [18F]Phe-BF3 of the brain, U87MG tumor xenograft, and site of inflammation, respectively. Maximum intensity projection (MIP) images show activity accumulation in tumor, gallbladder, and bladder. Figure adapted with permissions from Sci. Adv. 2015, 1(8): e1500694 [120], under a Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) License. (c) Radiofluorination of an unactivated C–H bond (i.e., lacking a leaving group or an activating proximal functional group) and radiofluorination of an activated C–H bond, via a triflate leaving group for nucleophilic substitution.

Figure 4. Somatostatin receptor imaging. (a) Chemical structure of [68Ga]Ga-DOTA-TATE. (b) SSTR2 expression in normal tissues and neoplastic tissues. Reproduced with permissions from Pharmacol. Rev. 2018, 70(4): 763–835 [128]. (c) In vivo SSTR2 imaging in a patient with metastatic low-grade cecal NET. [111In]In-pentetreotide scintigraphy (left) with [68Ga]Ga-DOTA-TATE PET (right) was performed before radiotherapy. In liver, retroperitoneal and thoracic lymph nodes, and bones, PET shows multiple metastases, many of which are undetectable on scintigraphy. Figure reproduced with permission from J. Nucl. Med. 2016, 57(12): 1949–1956 [129]. Copyright 2016 Society of Nuclear Medicine and Molecular Imaging.
2.2. Probes Based on Drugs

Drugs and drug candidates can be used to develop radiopharmaceutical agents. The primary concern with this approach is how the radiolabel group affects the bioactivity of the drug. For instance, the chemotherapeutic agent 5-fluorouracil was radiolabeled with $^{18}$F and used to differentiate malignant tissues from inflammatory lesions in preclinical models [130]. The tyrosine kinase inhibitor (TKI) erlotinib was radiolabeled with $^{11}$C and used in the clinic to assess the mutational status of the epidermal growth factor receptor (EGFR) in a cohort of nonsmall lung carcinoma patients [42]. $^{18}$Fafatinib, a second-generation TKI targeting EGFR, is undergoing similar clinical investigations [46]. The C-X-C chemokine receptor 4 antagonist plerixafor was directly radiolabeled with $^{64}$Cu by leveraging its chelating properties as a bicyclam [131]. Except for $^{64}$CuCu-plerixafor, the chemical structure of the targeting pharmacophore in these examples was left unmodified; an existing atom in their structure was replaced with a radioactive isotope.

In recent years, many major advances in nuclear medicine for cancer imaging come from probes derived from drug candidates. As an example, prostate-specific membrane antigen (PSMA) is a membrane-bound glutamate carboxypeptidase that is expressed in prostate cancer, and neovascularature of solid malignancies [132]. Initial efforts for targeting PSMA led to the development of a radiolabeled monoclonal antibody, $^{[111]}$In-capromab pendetide [133]. However, $^{[111]}$In-capromab pendetide was never widely adopted due to its reliance on SPECT technology and the fact that it was directed against an intracellular epitope, resulting in poor sensitivity as only necrotic cells were recognized. In 2001, Kozikowski et al. reported a class of urea-based inhibitors that targeted the enzymatic domain of PSMA [134]. This led to the development of PET-based PSMA radiolabeled with $^{18}$F or $^{68}$Ga (Figure 5), with $^{[68]}$Ga-Ga-PSMA-11 being the most widely used. These imaging agents are being used to guide RLT in patients with metastatic castration-resistant prostate cancer (mCRPC) in clinical trials [93].

![Figure 5. Prostate-specific membrane antigen imaging. (a) Chemical structures of several PSMA imaging agents. The four radiopharmaceuticals share a Glu-urea-Lys binding motif (in blue). (b) $^{[68]}$Ga-Ga-PSMA-11 PET maximum intensity projection (MIP) images at baseline and 3 months after $^{[177]}$Lu-Lu-PSMA-617 treatment in eight patients with PSA decline of $\geq 98\%$ in a prospective phase II study. Lesions with standardized uptake value (SUV) over three are highlighted in red. PSA values (ng/mL) are indicated below MIP images. Figure reproduced with permission from J. Nucl. Med. 2019, Jnumed.119.236414 [93]. Copyright 2019 Society of Nuclear Medicine and Molecular Imaging.](image-url)
Another biological target with revived interest is the fibroblast activation protein (FAP). FAP is a cell-surface serine protease that is expressed by fibroblasts. Cancer-associated fibroblasts (CAFs) remodel the extracellular matrix of the tumor microenvironment and facilitate growth and invasion [53]. In 2003, antibody-based imaging of FAP was investigated with $[^{131}I]$-sibrotuzumab [135], but efforts were hindered by slow pharmacokinetics and poor resolution. A decade later, Jansen et al. identified selective inhibitors of FAP based on a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold [136]. Based on this work, Lindner et al. were able to develop small molecule FAP-targeting PET imaging agents (Figure 6) [137]. Kratochwil et al. reported that $[^{68}Ga]$Ga-FAPI-04 was taken up by 28 types of cancer, showing itself to be a tumor agnostic agent [54]. The authors are optimizing lead structures to identify companion radiotherapeutic agents [55].

Monoclonal antibodies (mAbs) have been radiolabeled for cancer imaging since the 1970s [138]. However, interest waned briefly due to poor pharmacokinetics, immunogenic responses, low sensitivity and resolution of SPECT, and costs. New developments in oncology have revitalized interest in mAbs or antibody derivatives-based imaging including the clinical success of high-affinity mAbs as cancer therapeutics (e.g., trastuzumab, cetuximab, and bevacizumab) [139], the identification of novel cancer-associated proteins and splice-variants [140], and improved isotope production and radiolabeling strategies [141,142]. Immuno-PET can be a valuable development tool for mAb-based therapies like antibody–drug conjugates. Moreover, immuno-PET can be used in combination with other radiopharmaceuticals to select patients for individualized treatment to improve cost effectiveness [143].

![Figure 6. Fibroblast activation protein imaging.](image-url)
For example, radiolabeled checkpoint inhibitors are being evaluated in the clinic to see if they can be used to predict response for immunotherapy (Figure 7) [100].

**Figure 7.** Programmed cell death protein (PD-1)/programmed death-ligand 1 (PD-L1) imaging. (a) Blocking the binding of PD-L1 to PD-1 with an immune checkpoint inhibitor (anti-PD-L1 or anti-PD-1) allows T cells to kill tumor cells. Figure courtesy of Terese Winslow for the National Cancer Institute © (2020) Terese Winslow LLC, U.S. Govt. has certain rights. (b) PET scans of two patients imaged with [18F]FDG that measures glucose metabolism (left), [18F]BMS-986192 that measures PD-L1 expression (middle), and [89Zr]Zr-nivolumab (right) that measures PD-1 expression. Heterogenous tracer uptake observed between and within lesions. Figure was reproduced with permission from *Nat. Commun.* 2018, 9: 4664 [100], under a Creative Commons Attribution 4.0 International License.
2.3. Chemical Screens

Chemical screens have been used extensively for drug development, but is not commonly applied in radiopharmaceutical settings, at least not directly. However, it represents a promising strategy that can enable the discovery of new potent ligands with the requisite structure for radioisotope conjugation and the effective pharmacokinetics for imaging. Chemical screens assess the interaction of a library of structurally-diverse molecules to a target of interest; in an ideal scenario, a specific pharmacophore will be identified as having some degree of binding in comparison to others in the library [144]. Chemical screens have evolved from manual bioactivity assays of a group of ligands to techniques that range from high-throughput screens of thousands of compounds [145,146] to computational screens that assess binding affinity between a ligand and a target via docking simulations [147,148].

To generate diverse chemical libraries, a strategy is to use medium- or high-throughput combinatorial chemistry [149]. There is an increasing demand from industry and academia to develop new methods of generating structurally complex compounds in parallel, enabling a greater exploration of the chemical space. Yet, with the advances in combinatorial and synthetic chemistry come logistical challenges. Screening thousands, if not millions, of compounds, inevitably lead to issues as each compound must not only be purified and characterized but also assayed en masse [147]. As such, strategies have evolved into assaying mixtures of compounds towards a specific target or system and identifying potent compounds from these complex mixtures.

To identify hits in a complex mixture of compounds, screening strategies include DNA-encoded libraries [150–153], biological libraries (e.g., phage-display) [154–159], and one-bead-one-compound (OBOC) libraries [160,161]. These strategies construct pharmacophores by ligating discrete building blocks of chemicals. The procedure for assaying, separating, and identifying binders differs between methods, and readers are encouraged to further read the directed reviews for a more thorough explanation. Briefly, as pharmacophores increase in length, the diversity of the molecules within the library increases exponentially. For identification, each compound carries a chemical or physical barcode or is identified post hoc via analytical techniques such as mass spectroscopy. For example, binders from DNA-encoded libraries can be identified via their DNA tag through PCR and sequencing [150], and binders from OBOC libraries can be physically displaced from the bead and identified using a chemical tag [162], mass spectroscopy [163], or techniques like Edman degradation for peptides [164].

An example of radiopharmaceutical development from a chemical screen is the development of LLP2A, a pharmacophore with picomolar binding affinity to integrin \( \alpha_4\beta_1 \). LLP2A was identified using a diverse OBOC library screen followed by a focused OBOC library screen using Jurkat cells expressing integrin \( \alpha_4\beta_1 \) [165]. The diverse library (5.4 \( \times \) 10\(^{10} \) permutations) was designed around the tripeptide LDV, the minimal sequence required for binding to integrin \( \alpha_4\beta_1 \) [166] and a 2-(4-(3-o-tolylureido)phenyl)acetyl N-terminal moiety, previously shown to enhance binding [167]. Screening of this library revealed that (1) unnatural L, D, and V-like amino acids could enhance binding, (2) amino acids proximal of the C-terminus were unnecessary, and (3) 2-methylphenylurea was the ideal N-terminus cap. A focused library with these elements was used in conjunction with a pharmacological blocker and a negative selection control to obtain LLP2A. LLP2A was used successfully for near-infrared fluorescence imaging and later adapted for PET imaging by replacing the fluorophore with a radiometal complex (Figure 8). The resulting radiopharmaceutical, \(^{64}\text{Cu}\)Cu-LLP2A, showed good tumor uptake and contrast ratios in preclinical models [168,169] and is currently being investigated in phase I clinical trial for multiple myeloma imaging [74].
Another recent example is the use of a unique dual pharmacophore display DNA-encoded library by Wichert et al. to identify a novel inhibitor of carbonic anhydrase IX (CA-IX) [153]. In brief, 550 unique chemical constructs were conjugated to a 48-mer oligonucleotide, carrying a six-nucleotide sequence for identification, making up Library A. Library B, containing 202 compounds, was then constructed with a nucleotide sequence that could hybridize with Library A and also transfer a unique coding sequence. The oligonucleotide sequence in Library A acted as the template for PCR amplification. CA-IX was fixed on a solid support and the combined library (111,100 compounds) was subjected to affinity capture to identify potential binders. The A-493/B-202 pairing was found to be highly enriched and demonstrated twofold improved binding to CA-IX as compared to acetazolamide, a positive control. Optimization of the spacer between the two pharmacophores yielded a candidate with a $K_d$ of 2.6 nM (~10-fold improvement), which was adapted for imaging [153,170,171]. Minn et al. conjugated a bifunctional chelator to the dual pharmacophore for $^{64}$Cu-labeling and PET imaging [171]. $[^{64}$Cu$]$Cu-XYIMSR-06 showed excellent uptake in a clear cell renal cell carcinoma xenograft model and high tumor-to-blood, -muscle ratios of $>100$ within 24 h.

3. Radiochemistry

Following conceptualization, identification of a ligand, and design, radiolabeling is the next step in the developmental process for a radiopharmaceutical. Many radioisotopes can be used for
PET imaging, as shown in Table 2. Although each of these radioisotopes emits positrons, they have differences in physical half-life, branching ratio, positron range, and chemical reactivity. This raises the question, “How does one select the appropriate radioisotope and radiolabeling strategy for a pharmacophore?” The most straightforward answer would be to select a radiolabel that does not abrogate bioactivity of the pharmacophore. However, there are other considerations such as:

**Positron range:** Positrons emitted from the radioisotope travel a certain distance in the tissue before encountering an electron and causing an annihilation event. The traveled distance is proportional to the positron energy, known as the positron range [172]. This causes uncertainty for determining the exact location from which the positron originated from, reducing spatial resolution. Radioisotopes with lower positron ranges are preferred.

**Suitable physical half-life:** The radioisotope selected for labeling should approximate the biological half-life of the pharmacophore and accommodate clinical logistics if translation is warranted. In particular, $^{11}$C ($t_{1/2}$: 20.4 min), $^{18}$F ($t_{1/2}$: 109.7 min), and $^{68}$Ga ($t_{1/2}$: 67.7 min) are suitable for labeling small molecules, peptides, and affibodies that clear rapidly from circulation on the order of minutes to hours, whereas longer-lived isotopes like $^{124}$I ($t_{1/2}$: 100.2 h) and $^{89}$Zr ($t_{1/2}$: 78.4 h) are suitable for labeling antibodies, antibody fragments, and nanoparticles that stay in circulation on the order of hours to days. Some isotopes with intermediate half-lives like $^{64}$Cu ($t_{1/2}$: 12.7 h) and $^{86}$Y ($t_{1/2}$: 14.7 h) are suitable for many types of molecules.

**Molar activity:** Molar activity (MA) is defined as the amount of radioactivity per mole of a compound [173]. For saturable targets, it is better to have radiopharmaceuticals with “high” MA as the unlabeled species can compete for uptake. The concept of “high” MA varies for radionuclides, dependent largely on half-life. For instance, MA $>185$ GBq/µmol is considered “high” for $^{18}$F-labeled radiopharmaceuticals [174]. The presence of contaminants (e.g., nonradioactive isotope species) in reaction vessels or tubing reduce MA. Moreover, the production of some radioisotopes may necessitate the addition of a carrier or a stable isotopic species (e.g., $[^{18}$F]F$_2$), further decreasing MA [175]. Reactions with low labeling efficiency or that require large amounts of precursor can still achieve high MA, as long as the desired labeled product can be readily separated. Although optimal imaging contrast and tissue uptake is not always correlated with MA [176,177], care should be taken to ensure that injected ligand dose does not exceed practical (clinical) limits [178].

**Ease of labeling:** To minimize synthesis time and radioactive decay, one-step radiolabeling strategies that can proceed with fast kinetics are ideal. Sometimes a reaction can be heated to increase its kinetics, but this strategy should only be applied to pharmacophores that are not heat labile (e.g., small molecules or selected peptides).

**Availability of radioisotope:** Radioisotope selection can be dictated by infrastructure. Radioisotopes can be produced from reactors, accelerators, cyclotrons, and generators [179]. Some radioisotopes can be obtained from multiple production routes [180]. It is possible to ship radiopharmaceuticals (or starting radioactivity) from a central pharmacy (e.g., $[^{18}$F]FDG and $[^{64}$Cu]CuCl$_2$), but there are exceptions. If a radiopharmaceutical requires a short-lived isotope (e.g., $^{18}$C- and $^{15}$O-labeled compounds, $[^{82}$Rb]RbCl$_2$), an onsite cyclotron or generator is required as its half-life prevents distribution.

### Table 2. Radioisotopes for PET imaging. Adapted from Conti and Eriksson [172], Holland et al. [181], and Berger et al. [182].

| Radioisotope | Half-Life | Decay Mode | Mean $\beta^+$ Energy [MeV] | Mean Positron Range in Water [mm] | Production Route |
|-------------|-----------|------------|-----------------------------|-----------------------------------|------------------|
| $^{11}$C    | 20.4 min  | $\beta^+$  | 0.386                       | 1.2                               | $^{14}$N(p,α)$^{11}$C |
| $^{13}$N    | 10.0 min  | $\beta^+$  | 0.492                       | 1.8                               | $^{16}$O(p,α)$^{13}$N |
| $^{15}$O    | 2.0 min   | $\beta^+$  | 0.735                       | 3.0                               | $^{15}$N(p,α)$^{15}$O |
| $^{18}$F    | 109.7 min | $\beta^+$  | 0.250                       | 0.6                               | $^{18}$O(p,α)$^{18}$F |
### Table 2. Cont.

| Radioisotope | Half-Life | Decay Mode | Mean $\beta^+$ Energy [MeV] | Mean Positron Range in Water [mm] | Production Route |
|--------------|-----------|------------|-----------------------------|----------------------------------|------------------|
| $^{44}$Sc    | 4.0 h     | $\beta^+$ (94.3%) | 0.632                       | 2.4                              | $^{44}$Ti/$^{44}$Sc generator |
| $^{64}$Cu    | 12.7 h    | $\beta^+$ (17.6%) | 0.278                       | 0.7                              | $^{64}$Ni(p,n)$^{64}$Cu, $^{67}$Zn(p,n)$^{64}$Cu |
| $^{68}$Ga    | 67.7 min  | $\beta^+$ (88.9%) | 0.836                       | 3.5                              | $^{68}$Ge/$^{68}$Ga generator |
| $^{82}$Rb    | 1.3 min   | $\beta^+$ (81.8%) | 1.535                       | 7.1                              | $^{82}$Sr/$^{82}$Rb generator |
| $^{86}$Y     | 14.7 h    | $\beta^+$ (11.9%) | 0.535                       | 1.9                              | $^{86}$Sr(p,n)$^{86}$Y |
| $^{89}$Zr    | 78.4 h    | $\beta^+$ (22.7%) | 0.396                       | 1.3                              | $^{89}$Y(p,n)$^{89}$Zr |
| $^{124}$I    | 100.2 h   | $\beta^+$ (11.7%) | 0.687                       | 2.8                              | $^{124}$Te(p,n)$^{124}$I |

$\beta^+$ = positron decay.

#### 3.1. Radiolabeling Strategies

Strategies for radiolabeling largely fall under two categories: direct labeling and indirect labeling using prosthetic groups. Direct radiolabeling is usually reserved for small molecules as prosthetic conjugation may introduce steric bulk that negates bioactivity. Because carbon and fluorine are ubiquitous elements of organic-based pharmacophores, and $^{11}$C and $^{18}$F are readily produced by a cyclotron, they are the two most investigated PET radioisotopes. Precisely, $^{11}$C is used to label small molecules, particularly those used in brain imaging. Moreover, $^{11}$C is commonly produced as $[^{11}$C]CO$_2$, which can be converted to $[^{11}$C]CH$_3$I for methylation or to $[^{11}$C]acyl chloride for amine conjugation [183–185]. $[^{11}$C]CH$_4$ is another viable synthon for radiolabeling, with equivalent or even higher molar activities [186]. Like $[^{11}$C]CO$_2$, $[^{11}$C]CH$_4$ can be converted to $[^{11}$C]CH$_3$I for methylation [187].

Fluorination strategies rely largely on nucleophilic substitution ($S_{N2}$ or $S_{NAr}$) of $[^{18}$F]fluoride, with an appropriate leaving group (e.g., triflate) appended at the desired site of the molecule(Figure 3). Several metal-catalyzed radiofluorination methods have been developed that can expedite this process [185,188]. Electrophilic-based radiofluorination methods have also been explored. $[^{18}$F]F$_2$ has been used for electrophilic radiofluorination; however, given its reactivity and corrosiveness, effort towards milder electrophilic reagents have been pursued [189]. This has led to the development of reagents such as $[^{18}$F]NFSi [190] and $[^{18}$F]F-Selectfluor [191]. These methods are effective for labeling peptides that cannot tolerate nucleophilic substitution conditions [192]. However, these approaches can suffer from low molar activity and thus are better suited for radiopharmaceuticals that target transporters. The chemistry of $^{18}$F and $^{11}$C encompasses a field greater than this review can cover and readers are encouraged to peruse the cited reviews for a greater breadth of information.

Pharmacophores that lack a suitable site for direct labeling or cannot withstand the requisite harsh labeling conditions can use a prosthetic group. Prosthetic groups are generally small molecule-based constructs that have been optimized to coordinate radionuclides [193]. For biological considerations, they are appended to a site that is not required for binding (either determined experimentally or predicted using docking/modeling studies). Prosthetic groups are usually attached via a linker which can act as a pharmacokinetic modifier [194]. There are many radioprosthetic groups designed for $^{18}$F-labeling, and they are selective for different functional groups (e.g., carboxylic acids, thiols, amines, azides, etc.) [195]. The prosthetic group can be labeled first and then conjugated to the pharmacophore.
Bifunctional chelators are used widely in radiopharmaceutical development to chelate different radiometals [198]. A single chelator may be able to coordinate different radiometals, and a radiometal can be coordinated by different chelators [198]. Given the number of radiometals and chelators that exist, this nearly ensures that there will be a suitable radiometal/chelator combination for any type of pharmacophore [198]. For example, peptides and small molecules can be radiolabeled with $^{68}$Ga, $^{44}$Sc, or $^{64}$Cu using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (DOTA), while mAbs can be radiolabeled with $^{64}$Cu using 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) or with $^{89}$Zr using desferrioxamine (DFO) [141]. Like with linkers, chelators can also modulate distribution [199]. Perhaps the most intriguing aspect of bifunctional chelators is that some chelators like DOTA can chelate therapeutic isotopes as well (e.g., $^{177}$Lu and $^{225}$Ac). This represents a simple pathway for the development of theranostic pairs for cancer. Moreover, there is the potential to develop dual-labeled radiotheranostics with a chelator for a therapeutic radioisotope and another prosthetic group for a PET radioisotope (e.g., silicon-fluoride or trifluoroborate) [200–202].

3.2. Automation

Once a lead radiopharmaceutical is identified, the radiosynthesis is automated to optimize time and resource commitments. A synthesis module is usually housed within a hot cell (Figure 9) with operations controlled by an external computer. The module can perform the synthesis, purification, and reformulation automatically, without user intervention. The radiopharmaceutical is automatically dispensed into a presterilized vial. Automation can reduce the potential radiation exposure to personnel, simplify multistep syntheses, and ensure reproducibility and consistency of the radiopharmaceutical (yield, purity, and molar activity) in compliance with current good manufacturing practice (GMP). Moreover, once an automation process is established, the technology can be adopted by other centers with similar equipment, facilitating greater access.

![Radiopharmaceutical automation](image-url)
3.3. Quality Control

Prepared radiopharmaceuticals must pass quality control (QC) tests before they can be released for patient use. QC for radiopharmaceuticals can be divided into physicochemical or biological tests. Institutes must comply with QC regulations to ensure safety and efficacy. For physicochemical tests, the parameters measured are appearance, radionuclide identity and purity, activity concentration, radiochemical purity, residual solvents, specific activity, pH, osmolality, and stability. For biological tests, the parameters measured are bacterial endotoxin test, filter membrane integrity, and sterility. Readers are encouraged to read the article by Vallabhajosula [203] to see the different methods for testing each parameter. It should be noted that there are regional pharmacopeias that dictate QC methodologies, and that institutions must adhere to a procedure if it is stated in a pharmacopeia. Although most parameters can be tested before release, sterility testing normally has a 2-week delay as it requires incubation in soybean casein digest and fluid thioglycollate medium to test for bacterial and fungal growth; hence, it is not tested before release. Usually, a few production runs are done and once several tests confirm sterility, subsequent runs can be injected in patients as long as bacterial endotoxin and filter membrane integrity pass. Sterility is still assayed knowing that results will only be known long after injection [203,204].

4. Preclinical Experiments

The conception of imaging radiopharmaceuticals requires careful planning of preclinical studies to confirm their suitability for the intended application, guide their optimization, and support clinical translation. In this section, we aim to provide a basic list of experiments that should be performed for characterization. Although the order of these steps will vary based on individual laboratory workflows, it is possible to minimize development costs by focusing on critical assays early in the process. In particular, low-cost discriminating in vitro assays like binding affinity and in vitro stability should be done earlier before advancing to in vivo studies.

4.1. Binding Affinity

In vitro assays represent an inexpensive and quick method of assaying new probes for bioactivity, while being highly predictive of the potential success of the radiopharmaceutical [205]. A radioligand competition binding assay is generally performed on a cell line or commercial membranes that express the target of interest [206]. The probe will be incubated with a competing ligand. Although either the probe or competitor can be radiolabeled, it is often simpler to use a long-lived commercial radioactive competitor (i.e., $^{125}$I-labeled). Ideally, the dissociation constant ($K_d$) of the competitor is known, so that inhibition constant ($K_i$) can be calculated [206]. Other methods like surface plasmon resonance [207], biolayer interferometry [208], isothermal titration calorimetry [209], and microscale thermophoresis [210] can be used to measure binding affinity. These methods do not require radioactivity, offer higher throughput, and, depending on the method used, inform on binding kinetics; however, they require a lot of optimization for test conditions.

4.2. Internalization and Efflux Assays

An important determinant of tumor uptake is cellular internalization and retention of the radiopharmaceutical [205]. Internalization is beneficial since it increases uptake when rates of efflux are low. In particular, radiometals have residualizing properties that are advantageous since once they are internalized, they remain in cell lysosomes (such as $^{68}$Ga and $^{64}$Cu) [211,212]. Internalization and efflux assays can be performed to determine those properties. They consist of incubating cells expressing the target of interest with the radiopharmaceutical; thereafter, samples from reaction media or contents of the lysed cells are assayed for their radioactivity at set time points. If desired, a mild acid wash can be applied to cells to determine membrane-bound fraction before lysis.
4.3. Stability

Although stability can sometimes be inferred from PET images and biodistribution studies by being attentive to uptake in specific organs (e.g., $^{64}$Cu in liver, $^{124}$I in thyroid, $^{18}$F in bone) \[28,104\], assays evaluating this specifically are warranted. Instability might be secondary to transchelation, peptide cleavage, dehalogenation, metabolism, and other degradations of the probe. This can be assayed in vitro by incubating the radiotracer in plasma and assaying on radio-HPLC and/or radio-TLC \[213\]. However, in vivo studies are more accurate since the tracer is exposed not only to plasma enzymes but also to tissue metabolism \[214\]. At set time points after injection of the tracer in animals, plasma from blood and urine can be collected and then assayed on radio-HPLC and/or radio-TLC to determine the fraction of intact radiotracer. For peptide-based tracers, coadministration with peptidase inhibitors can inform us about enzymatic stability and increasing bioavailability and tumor uptake \[215,216\].

4.4. Plasma Protein Binding

Radiopharmaceuticals may bind to different plasma proteins in blood during systemic circulation. Binding to these proteins can affect a radiopharmaceutical’s half-life and distribution in tissue \[217\]. If a radiopharmaceutical is lipophilic, it has a higher propensity to associate with plasma proteins \[218\]. Ultrafiltration is a common experiment used to measure plasma binding \[219\]. Briefly, a radiopharmaceutical is incubated with plasma or purified proteins (e.g., albumin). The samples are loaded onto ultrafiltration units (commonly 30 kDa cut-off) and centrifuged. The counted eluant represents the fraction of unbound radiopharmaceutical. Though this method is quick and simple, caution should be taken as some radiopharmaceuticals may bind nonspecifically to the filtration membrane. An alternative method to measure plasma binding is high-performance frontal analysis, which is based on gel filtration column chromatography \[220\]. This technique is said to correlate well with ultrafiltration and minimizes nonspecific binding \[220\].

4.5. Immunoreactivity

Presently, the most common strategy for radiolabeling mAbs for PET is through the use of bifunctional chelators (e.g., desferrioxamine derivatives). These chelators are usually conjugated to the mAb via terminal amines. Since the mAb is modified through the conjugation and radiolabeling process, the immunoreactive fraction may be negatively affected. This reduces binding to the target of interest and in turn, lowers tumor uptake. The Lindmo method has been used extensively to determine the immunoreactive fraction of radiolabeled mAbs \[221\]. It is a cell-based assay that measures binding at different antigen concentrations and extrapolates to conditions that represent infinite antigen excess. Because it relies on cells, the reliability and robustness of the system are limited by intercellular heterogeneity. Recently, Sharma et al. reported a bead-based radioimmunoassay that can determine the immunoreactive fraction (named “target-binding fraction”), which can be used for radiolabeled antibodies and other targeting vectors as well \[222\].

4.6. Antagonist and Agonist Assays

For some receptor systems like GPCRs, information about whether a radiopharmaceutical behaves as an agonist or antagonist can be important. This property can dictate the extent of internalization of a radiopharmaceutical. A way of determining agonistic/antagonistic property is by analyzing dose–response curves \[223\]. Briefly, agonists elicit a dose-dependent response, while antagonists do not yield response and can be further assessed by their ability to block the measured signal in the presence of an agonist resulting in a rightward shift of the curve. Partial agonists, while eliciting a response, will only yield a submaximal response as compared to an agonist. Dose–response can also be measured via the release of secondary messengers (e.g., calcium, cAMP, etc.) or by other assays such as FRET/BRET-based assays \[224\].
4.7. Imaging

PET imaging of tumor xenografts implanted in murine models is an attractive method of quickly screening probes [225,226]. Although in vivo studies are inherently more costly, they generate important information indicative of success. Different tumor models include animal, human, or patient-derived xenografts. There is also a trend in nuclear medicine to use transduced models. Transduced tumor models, while convenient for internal comparison and optimization, may not be reflective of the physiological conditions (e.g., PC3 PIP cell line vs. LnCAP cell line used in PSMA research) [178,227]. Other overlooked aspects of in vivo evaluations are the age and gender of the animals. Tumor uptake values in young female mice tend to be higher than in older male mice because of the differences in distribution volume.

Dynamic PET imaging, covering the time from injection of the tracer onward, informs about tracer kinetics (including the time needed to achieve optimal contrast), ability to localize to tumor tissue, clearance routes, and normal tissue uptake. By drawing regions-of-interest (ROIs) on the acquired images, uptake in physiological compartments can be quantified. With short-lived tracers (e.g., $^{18}$F- or $^{68}$Ga-labeled), the same animal can be imaged with different tracers on subsequent days, thus optimizing the use of laboratory animals. Animals are typically given *ad libitum* access to food and water; however, there are cases where fasting may be required (e.g., $[^{18}\text{F}]$FDG) [228]. Body temperature should be maintained during the uptake period and image acquisition [228]. Pitfalls of using small animals for imaging include partial volume effect [229], which decreases the accuracy of uptake measurements on small organs even when fused with anatomical data (CT or MRI). The use of prolonged anesthesia can also alter pharmacokinetics and clearance of the radiotracer [230]. Nevertheless, PET imaging can be a great screening tool before proceeding with more resource-intensive studies like ex vivo biodistribution.

4.8. Biodistribution by Dissection

Biodistribution studies performed by animal dissection are standard practice in the field to determine tracer uptake in tissues. Tumor-bearing animals are injected with the radiopharmaceutical and euthanized at specific time points. Tumor and major organs are harvested and assayed for their radioactivity in an automated gamma counter. Tissue uptake is usually reported as a fraction of injected radioactivity per mass of tissue (%IA/g) decay corrected to the time of injection. Blood is also collected during biodistributions since tracer blood levels can explain observed dynamics. The data can be compared to image-derived biodistribution data, improving scientific rigor.

4.9. Specificity

Blocking studies, either in imaging or biodistribution, is an important step to determine radiopharmaceutical specificity for its target. Radiopharmaceutical accumulation in tissue can be driven by different mechanisms that do not involve the target, for instance, enhanced permeability and retention (EPR) [231] effect or passive diffusion. Blocking studies can be performed by coinjecting a 100-fold of the mass of the nonradioactive standard and confirming reduced uptake in the target tissue (at least 30–50% could be considered good). It is also possible to use a different ligand/inhibitor for the target, but its pharmacokinetic properties and affinity must be similar to that of the radiopharmaceutical. Reviewing literature might provide important clues for suitable blocking agents including dose and route of administration. Other ways to test specificity are to evaluate the radiopharmaceutical in models with differing levels of target expression (e.g., a knockout model) and to perform autoradiographic correlation with immunohistochemistry.

4.10. Time Points

The selection of appropriate time points is vital for in vivo preclinical studies and is based on expected tracer kinetics, clinical logistics, dosimetry calculations, and radioactive decay. As mentioned, dynamic imaging may inform on appropriate time points for imaging and biodistribution studies.
Moreover, time points should be selected that are in line with usual clinical workflows (e.g., 30–120 min post-injection for short-lived isotopes). To determine late pharmacokinetics, late biodistribution time points can be added to coincide with clinical logistics and peak tumor-to-background ratios. Those time points should be spaced over approximately five effective half-lives of the radiotracer. The number of time points recorded should be tailored for the application. If the study is only aimed at comparing uptake between tracers, two or three time points might be appropriate, whereas if it is aimed at determining effective half-life and dosimetry, then enough points should be used for mono- or biexponential decay modeling [232].

4.11. Dosimetry

Dosimetry calculations are an essential part of radiopharmaceutical development and are required for clinical translation [232]. It gives an estimation of the radiation dose that a patient receives from the radiopharmaceutical. For most diagnostic probes that incorporate short-lived radioisotopes (e.g., ⁶⁸Ga and ¹⁸F), it is less a concern since physical decay alone takes care of limiting patient exposure, providing reasonable administered activities. For longer-lived isotopes such as ⁸⁹Zr that are usually associated with antibody or antibody-derivatives imaging, dosimetry can be much higher. To compute dosimetry, according to Medical Internal Radiation Dosimetry (MIRD) methodology, biodistribution studies are typically conducted at multiple time points over five effective half-lives of the radiopharmaceutical [233]. Time–activity curves are fitted to exponential models, and then, the area under the curve is calculated to obtain residence time. These residence times can be entered in specialized dosimetry software like OLINDA/EXM to compute dosimetry. When extrapolating to humans for dosimetry, some adjustments have to be made to account for the organ size difference between species [234]. Because of cost, high-throughput capability, and relative ease of breeding and handling, rodents are the most popular animal model for imaging. Other animal species are also used to evaluate PET radiopharmaceuticals. For example, rhesus monkeys are commonly used to evaluate neuro-PET radiopharmaceuticals with respect to target engagement, distribution, and dosimetry [235].

4.12. Toxicity

Evaluation of radiopharmaceutical toxicity is usually performed for the candidate for clinical translation. Typically, toxicity is performed for the nonradioactive standard for diagnostic radiopharmaceuticals. Animals (typically a rodent species) are injected intravenously with a large multiple of the expected human mass of radiopharmaceutical (i.e., 1000-fold) calculated by taking into account specific activity attainable during production and expected radioactivity amount to be administered in humans [236]. A group injected with saline can be used as control. This follows the microdose approach for acute toxicity testing in a single species [236]. Animals are monitored for acute effects in the immediate recovery period and then for a prolonged time for chronic effects (usually 2 weeks). Monitored parameters typically include blood chemistry, complete blood counts, weight, animal behavior, signs of distress, and organ histopathology, but should be adapted for sites of known accumulation of the radiopharmaceutical from biodistribution studies and known toxicities of chemically similar compounds if that information is available.

5. Regulatory Considerations

Once a candidate radiopharmaceutical has been optimized and is ready for clinical translation, the next step is obtaining regulatory approval for clinical trials and then, eventually, for marketing authorization, if it is promising. Preclinical evaluations can be costly, time consuming, and resource intensive. Fortunately, regulatory agencies have begun to recognize the unique position of diagnostic radiopharmaceuticals and have drafted guidelines to fast track their evaluation.
5.1. Nonclinical Evaluation of Radiopharmaceuticals

An important guideline for nonclinical evaluations is the one published by the International Council on Harmonization (ICH): “ICH guidelines M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals.” Generally aimed at pharmaceuticals, this document details toxicity studies and microdose trials (for exploratory clinical trials) [236]. It is widely adopted by international regulatory bodies like the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada.

Under the auspice of ICH, the FDA published a guidance document for industry that is aimed at diagnostic radiopharmaceuticals and which is more relaxed than for typical pharmaceuticals [237]. This is because radiopharmaceuticals for diagnostic studies are generally administered in extremely low doses that are unlikely to have pharmaceutical effects. Furthermore, diagnostic radioisotopes have low emission profiles and are usually short-lived, resulting in relatively low dosimetry. The FDA defines a microdose as a mass of 100 µg or less of the radiopharmaceutical. For proteins, the maximum dose is set at 30 nanomoles or less to account for differences in molecular weight. Recommended studies before initiation of phase I clinical trials include pharmacology extended single-dose toxicity and pharmacokinetics.

Pharmacology includes in vitro and in vivo characterizations. For instance, measurement of affinity to target, biodistribution studies, and dosimetry calculations.

Extended single-dose toxicity can be assayed in a single species (typically in rodents) at a large multiple of expected human doses (i.e., 1000-fold). Animals of both sexes should be included, and the route of exposure should be the same as the one intended for use in patients. In such studies, animals are monitored over 14 days with interim necropsy and parameters monitored include clinical signs, body weight, blood chemistry, hematology, and histopathology. Dose scaling between animals and humans should be adjusted on a milligram per kilogram basis for intravenous and a milligram per square meter basis for oral administration.

Pharmacokinetics (usually performed before phase III) would include absorption, distribution, excretion, and metabolism, in vivo and in vitro. Tests should also be performed to assess the possibility of interactions with other drugs if appropriate, depending on the target.

The EMA has similar guidelines available as a draft [238]: “Guideline on the nonclinical requirements for radiopharmaceuticals, Draft.” It also relaxes requirements for preclinical evaluation of radiopharmaceuticals, in particular for minimal modifications of known radiopharmaceuticals or pharmaceuticals. Those are defined as: radionuclide substitution in a known radiopharmaceutical, addition of a radionuclide to a known pharmaceutical, or minimal change to the nonradioactive part of a radiopharmaceutical.

In the case of a minimal change to the nonradioactive part of a new radiopharmaceutical, the required data before clinical trials include details of pharmacology, pharmacokinetics, and toxicology. For radiodiagnostics that fall under the microdose umbrella, the scope of the required data is less important (≤100 µg, ≤1/100 no-observed-adverse-effect-level (NOAEL), ≤1/100 pharmacological active dose OR ≤500 µg total), maximum five administrations with washout (six or more actual or predicted half-lives between dosing), and each dose (≤100 µg, ≤1/100 NOAEL, ≤1/100 pharmacological active dose) [238].

In all cases, conducted studies should be performed in accordance with good laboratory practice (GLP). In some settings, as close to GLP as possible is accepted. It is important to stress that alternative testing approaches to those detailed in the guidance documents may be acceptable. This should always be discussed with the responsible regulatory bodies to ensure that the planned study design is acceptable.

5.2. Exploratory Approaches for First-in-Human Studies

To expedite translation and to reduce time and resources, regulatory bodies are being more receptive to exploratory approaches for first-in-human studies [239]. In 2006, the FDA issued its guidance
for exploratory investigational new drug (eIND) studies [240]. Since PET radiopharmaceuticals are administered at subpharmacologic microdoses and present fewer potential risks, they can qualify for eIND studies. By definition, an eIND study describes a trial performed early in phase I, involves very limited human exposure and has no therapeutic or diagnostic intent. eIND studies are conducted before dose-escalation, safety, and tolerance studies. These studies can inform us on a candidate’s mechanism of action (e.g., binding property) and pharmacokinetics. Moreover, eIND can be used to drive selection of a lead product from a group of candidates based on human data rather than relying solely on preclinical data.

5.3. Marketing Authorization

The final step in porting a newly developed radiopharmaceutical to clinical use is obtaining marketing authorization from regulatory bodies. This final step will enable the sale and use of the radiotracer in clinical settings outside of clinical trials for the indications for which the marketing authorization was sought. This step is usually performed after extensive phase II/III clinical trials have concluded.

6. Perspectives and Summary

The design of radiopharmaceuticals is a complex endeavor (Figure 10). The choice of pharmacophore, radionuclide, radiolabeling strategy, and preclinical experiments, all have an essential role to play in creating a diagnostic radiotracer. Beyond what is discussed, readers should keep in mind other considerations. The identification and validation of a biomarker are just as important as radiopharmaceutical design [241]. As articulated by Nimmagadda et al., this extends to the appropriate selection of tumor models (animal, human, and patient-derived xenografts), implantation strategies (subcutaneous, orthotopic, and spontaneous tumors), and host strains (immunodeficient, immunocompetent, genetically modified, and humanized mice) [241]. These factors influence the outcome of experiments, the ability to compare with literature, and the potential for translation of a clinically useful radiotracer.

![Figure 10. An overview of the radiopharmaceutical developmental pathway. Radiopharmaceuticals undergo comprehensive (radio)chemical, in vitro, and in vivo characterization before they can advance into clinical testing.](image-url)
Successful discovery and development of a diagnostic PET radiotracer may not be the endgame, however. Many targets are also equally suited for therapeutic applications. With careful design choices, theranostic (i.e., therapeutic and diagnostic) radiopharmaceuticals can be developed. Examples of such success stories include Na$^{124}$I/Na$^{131}$I for thyroid cancer, $^{68}$Ga/$^{177}$LuGa/Lu-DOTA-TATE for neuroendocrine tumors, and $^{68}$Ga/$^{177}$Lu/$^{225}$AcGa/Lu/Ac-PSMA-617 for prostate cancer, with many more in development. With this approach, one can evaluate endoradiotherapy suitability by confirming target expression with the diagnostic radiopharmaceutical of the theranostic pair, enabling personalized medicine.

One fact is certain, molecular imaging is a quickly evolving field. Since 2012, four novel PET radiotracers received FDA approval for cancer indications. This represents one-third of all approved PET radiopharmaceuticals dating back to 1972. We anticipate this accelerating trend to continue as more groups than ever contribute to their development. Recognition by regulatory agencies of the unique status of diagnostic radiopharmaceuticals as well as collaboration between research groups and industry is poised to drive the translation of more of them to clinic. As more radiotracers shine their light on cancer, one thing is certain: the future for PET imaging is bright indeed.

Author Contributions: Conceptualization, J.L. and X.C.; writing—original draft preparation, J.L., E.R., and D.K.; writing—review and editing, J.L., E.R., K.-S.L., F.B., X.C.; supervision, F.B. and X.C.; funding acquisition, X.C. All authors have read and agreed to the published version of the manuscript.

Funding: Support for this work was provided by the Intramural Research Program of the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. J.L. is supported by a Canadian Institutes of Health Research Postdoctoral Fellowship.

Conflicts of Interest: The authors declare that no competing financial interest exists.

References
1. Boellaard, R.; Delgado-Bolton, R.; Oyen, W.J.G.; Giammarile, F.; Tatsch, K.; Eschner, W.; Verzijlbergen, F.J.; Barrington, S.F.; Pike, L.C.; Weber, W.A.; et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 328–354. [CrossRef] [PubMed]
2. Cherry, S.; Sorenson, J.; Phelps, M. Physics in Nuclear Medicine, 4th ed.; Saunders, Elsevier Inc.: Philadelphia, PA, USA, 2012; ISBN 9781416051985.
3. Acton, P.D.; Zhuang, H.; Alavi, A. Quantification in PET. Radiol. Clin. North Am. 2004, 42, 1055–1062. [CrossRef] [PubMed]
4. Liberti, M.V.; Locasale, J.W. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem. Sci. 2016, 41, 211–218. [CrossRef] [PubMed]
5. Griffith, L.K. Use of PET/Ct Scanning in Cancer Patients: Technical and Practical Considerations. Baylor Univ. Med. Cent. Proc. 2005, 18, 321–330. [CrossRef]
6. Lau, J.; Jacobson, O.; Niu, G.; Lin, K.S.; Bénard, F.; Chen, X. Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies. Bioconjug. Chem. 2019, 30, 487–502. [CrossRef]
7. Chen, K.; Chen, X. Design and Development of Molecular Imaging Probes. Curr. Top. Med. Chem. 2010, 10, 1227–1236. [CrossRef]
8. Bernard-Gauthier, V.; Bailey, J.J.; Berke, S.; Schirrmacher, R.; Leahy, J.W. Recent advances in the development and application of radiolabeled kinase inhibitors for PET imaging. Molecules 2015, 20, 22000–22027. [CrossRef]
9. Krebs, S.; Veach, D.R.; Carter, L.M.; Grkovski, M.; Fornier, M.; Mauro, M.J.; Voss, M.H.; Danila, D.C.; Burnazi, E.; Null, M.; et al. First-in-Human Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted Positron Emission Tomography. J. Nucl. Med. 2020. [CrossRef]
10. Silberstein, E.B.; Ryan, J. Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine. J. Nucl. Med. 1996, 37, 185–192.
11. Grewal, R.K.; Ho, A.; Schöder, H. Novel approaches to thyroid cancer treatment and response assessment. Semin. Nucl. Med. 2016, 46, 109–118. [CrossRef]
12. Fukuda, H.; Takahashi, J.; Fujivara, T.; Yamaguchi, K.; Abe, Y.; Kubota, K.; Sato, T.; Miyazawa, H.; Hatazawa, J.; Tada, M. High accumulation of 2-deoxy-2-fluorine-18-fluoro-D-galactose by well-differentiated hepatomas of mice and rats. J. Nucl. Med. 1993, 34, 780–786. [PubMed]
13. Carrasquillo, J.A.; Pandit-Taskar, N.; O'Donoghue, J.A.; Humm, J.L.; Zanzonico, P.; Smith-Jones, P.M.; Divgi, C.R.; Pryma, D.A.; Ruan, S.; Kemeny, N.E.; et al. 124I-huA33 antibody PET of colorectal cancer. *J. Nucl. Med.* 2011, 52, 1173–1180. [CrossRef]

14. Grassi, I.; Nanni, C.; Allegri, V.; Moriggi, J.J.; Montini, G.C.; Castellucci, P.; Fantl, S. The clinical use of PET with (11)C-acetate. *Am. J. Nucl. Med. Mol. Imaging* 2012, 2, 33–47. [PubMed]

15. Chen, W. Clinical applications of PET in brain tumors. *J. Nucl. Med.* 2007, 48, 1468–1481. [CrossRef] [PubMed]

16. Qi, Y.; Liu, X.; Li, J.; Yao, H.; Yuan, S. Fluorine-18 labeled amino acids for tumor PET/CT imaging. *Oncotarget* 2017, 8, 60581–60588. [CrossRef]

17. Ogawa, T.; Kanno, I.; Shishido, F.; Inugami, A.; Higano, S.; Fujita, H.; Murakami, M.; Uemura, K.; Yasui, N.; Mineura, K.; et al. Clinical value of PET with 18F-fluorodeoxyglucose and 1-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. *Acta Radiol.* 1991, 32, 197–202. [CrossRef]

18. Verbeek, H.H.G.; Plukker, J.T.M.; Koopmans, K.P.; De Groot, J.W.B.; Hofstra, R.M.W.; Muller Kobold, A.C.; Van Der Horst-Schriwers, A.N.A.; Brouwers, A.H.; Links, T.P. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. *J. Nucl. Med.* 2012, 53, 1863–1871. [CrossRef]

19. Mittra, E.S.; Koglin, N.; Mosci, C.; Kumar, M.; Hoehne, A.; Keu, K.V.; Iagaru, A.H.; Mueller, A.; Berndt, M.; Bullich, S.; et al. Pilot preclinical and clinical evaluation of (4S)-4-[18F]Fluoropropyl)-1-Glutamate (18F-FSPG) for PET/CT imaging of intracranial malignancies. *PLoS ONE* 2016, 11, e0148628. [CrossRef]

20. Dunphy, M.P.S.; Harding, J.J.; Veneti, S.; Zhang, H.; Burnazi, E.M.; Bromberg, J.; Omuro, A.M.; Hsieh, J.J.; Mellinghoff, I.K.; Staton, K.; et al. In vivo PET assay of tumor glutamine flux and metabolism: In-human trial of 18F-(2S,4R)-4-fluoroglutamine. *Radiology* 2018, 287, 667–675. [CrossRef]

21. Savir-Baruch, B.; Schuster, D.M.; Jarkas, N.; Master, V.A.; Nieh, P.T.; Halkar, R.K.; Nye, J.A.; Lewis, M.M.; Crowe, R.J.; Voll, R.J.; et al. Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma. *Mol. Imaging Biol.* 2011, 13, 1272–1277. [CrossRef] [PubMed]

22. Larson, S.M.; Morris, G.; Gunther, I.; Beattie, B.; Humm, J.L.; Akhurst, T.A.; Finn, R.D.; Erdi, Y.; Pentlow, K.; Dyke, J.; et al. Tumor localization of 16β-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. *J. Nucl. Med.* 2004, 45, 366–373. [PubMed]

23. Turkbey, B.; Men, E.; Shih, J.; Pinto, P.A.; Merino, M.J.; Lindenberg, M.; Bernardo, M.; McKinney, Y.L.; Adler, S.; Owenius, R.; et al. Localized prostate cancer detection with 18F FACBC PET: Comparison with MR imaging and histopathologic analysis. *Radiology* 2014, 270, 849–856. [CrossRef] [PubMed]

24. Dyke, J.; et al. Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F] FACPC) PET-CT in recurrent prostate carcinoma. *Mol. Imaging Biol.* 2011, 13, 1272–1277. [CrossRef] [PubMed]

25. Larson, S.M.; Morris, G.; Gunther, I.; Beattie, B.; Humm, J.L.; Akhurst, T.A.; Finn, R.D.; Erdi, Y.; Pentlow, K.; Dyke, J.; et al. Tumor localization of 16β-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. *J. Nucl. Med.* 2004, 45, 366–373. [PubMed]

26. Dehdashti, F.; Picus, J.; Michalski, J.M.; Dence, C.S.; Siegel, B.A.; Katzenellenbogen, J.A.; Welch, M.J. Positron tomographic assessment of androgen receptors in prostatic carcinoma. *Eur. J. Nucl. Med. Mol. Imaging* 2005, 32, 344–350. [CrossRef] [PubMed]

27. Oborski, M.J.; Laymon, C.M.; Lieberman, F.S.; Drappatz, J.; Hamilton, R.L.; Mountz, J.M. First use of 18F-labeled ML-10 PET to assess apoptosis change in a newly diagnosed glioblastoma multiforme patient before and early after therapy. *Brain Behav.* 2014, 4, 312–315. [CrossRef]

28. Dubash, S.R.; Merchant, S.; Heinimann, K.; Mauri, F.; Lavdas, I.; Inglese, M.; Kozlowski, K.; Rama, N.; Masrour, N.; Steel, J.F.; et al. Clinical translation of [18F]CMCT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer. *Eur. J. Nucl. Med. Mol. Imaging* 2018, 45, 2285–2299. [CrossRef]

29. Jadrar, H.; Desai, B.; Conti, P.S. Sodium 18F-fluoride PET/CT of bone, joint, and other disorders. *Semin. Nucl. Med.* 2015, 45, 58–65. [CrossRef]

30. Phase I Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1 - Full Text View - ClinicalTrials. Available online: https://clinicaltrials.gov/ct2/show/NCT02687230 (accessed on 16 April 2020).

31. Divgi, C.R.; Uzzo, R.G.; Gatsonis, C.; Bartz, R.; Treutner, S.; Yu, J.Q.; Chen, D.; Carrasquillo, J.A.; Larson, S.; Bevan, P.; et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: Results from the REDECT trial. *J. Clin. Oncol.* 2013, 31, 187–194. [CrossRef]

32. Hekman, M.C.H.; Rijpkema, M.; Aarnzen, E.H.; Mulder, S.F.; Langenhuijzen, J.F.; Oosterwijk, E.; Boerman, O.C.; Oyen, W.J.G.; Mulders, P.F.A. Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. *Eur. Urol.* 2018, 74, 257–260. [CrossRef]
32. Lau, J.; Lin, K.S.; Bénard, F. Past, present, and future: Development of theranostic agents targeting carbonic anhydrase IX. *Theranostics* 2017, 7, 4322–4339. [CrossRef]

33. Moek, K.L.; Waaijer, S.J.H.; Kok, I.C.; Suurs, F.V.; Brouwers, A.H.; Menke-Van Der Houven Van Oordt, C.W.; Wind, T.T.; Gietema, J.A.; Schröder, C.P.; Mahesh, S.V.K.; et al. 89Zr-labeled bispecific T-cell engager AMG 211 PET shows AMG 211 accumulation in CD3-rich tissues and clear, heterogeneous tumor uptake. *Clin. Cancer Res.* 2019, 25, 3517–3527. [CrossRef] [PubMed]

34. Pandit-Taskar, N.; Postow, M.A.; Hellmann, M.D.; Harding, J.J.; Barker, C.A.; O’Donoghue, J.A.; Ziolkowska, M.; Ruan, S.; Lyashchenko, S.K.; Tsai, F.; et al. First-in-Humans Imaging with 89Zr-D1-IB22M2C Anti-CD8 Minobody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. *J. Nucl. Med.* 2020, 61, 512–519. [CrossRef] [PubMed]

35. Jauw, Y.W.S.; Zijlstra, J.M.; de Jong, D.; Vugts, D.J.; Zweegman, S.; Hoekstra, O.S.; van Dongen, G.A.M.S.; Huisman, M.C. Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. *PLoS ONE* 2017, 12, e0169828. [CrossRef] [PubMed]

36. Jauw, Y.W.S.; O’Donoghue, J.A.; Zijlstra, J.M.; Hoekstra, O.S.; Willemin Menke-Van Der Houven Van Oordt, C.; Morschhauser, F.; Carrasquillo, J.A.; Zweegman, S.; Pandit-Taskar, N.; Lammertsma, A.A.; et al. 89Zr-immuno-PET: Toward a noninvasive clinical tool to measure target engagement of therapeutic antibodies in vivo. *J. Nucl. Med.* 2019, 60, 1825–1832. [CrossRef]

37. Börjesson, P.K.E.; Jauw, Y.W.S.; De Bree, R.; Roos, J.C.; Castelijn, J.A.; Leemans, C.R.; Van Dongen, G.A.M.S.; Boellaard, R. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. *J. Nucl. Med.* 2009, 50, 1828–1836. [CrossRef]

38. Weiss, I.D.; Huff, L.M.; Evbuomwan, M.O.; Xu, X.; Dang, H.D.; Velez, D.S.; Singh, S.P.; Zhang, H.H.; Gardina, P.J.; Lee, J.H.; et al. Screening of cancer tissue arrays identifies CXCR4 on adenocortical carcinoma: Correlates with expression and quantification on metastases using 64Cu-plerixafor PET. *Oncotarget* 2017, 8, 73387–73406. [CrossRef]

39. Lapa, C.; Schreder, M.; Schirbel, A.; Samnick, S.; Kortüm, K.M.; Herrmann, K.; Kropf, S.; Einsele, H.; Buck, A.K.; Wester, H.J.; et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values. *Theranostics* 2017, 7, 205–212. [CrossRef]

40. Wang, Z.; Zhang, M.; Wang, L.; Wang, S.; Kang, F.; Li, G.; Jacobson, O.; Niu, G.; Yang, W.; Wang, J.; et al. Prospective study of 68Ga-NOTA-NFB: Radiation dosimetry in healthy volunteers and first application in glioma patients. *Theranostics* 2015, 5, 882–889. [CrossRef]

41. Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma—Full Text View—ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03313323 (accessed on 16 April 2020).

42. Bahce, I.; Smit, E.F.; Lubberink, M.; Van Der Veldt, A.A.M.; Yaqub, M.; Windhorst, A.D.; Schuit, R.C.; Thunnissen, E.; Heideman, D.A.M.; Postmus, P.E.; et al. Development of [11C]Jerlotinib positron emission tomography for in vivo evaluation of EGFR receptor mutational status. *Clin. Cancer Res.* 2013, 19, 183–193. [CrossRef]

43. Liu, N.; Li, M.; Li, X.; Meng, X.; Yang, G.; Zhao, S.; Yang, Y.; Ma, L.; Fu, Z.; Yu, J. PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans. *J. Nucl. Med.* 2009, 50, 303–308. [CrossRef]

44. van Helden, E.J.; Elias, S.G.; Gerritsen, S.L.; van Es, S.C.; Boon, E.; Huisman, M.C.; van Grieken, N.C.T.; Dekker, H.; van Dongen, G.A.M.S.; Vugts, D.J.; et al. [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. *Eur. J. Nucl. Med. Mol. Imaging* 2020, 47, 849–859. [CrossRef] [PubMed]

45. Lindenberg, L.; Adler, S.; Turkbay, I.B.; Mertan, F.; Ton, A.; Do, K.; Kummar, S.; Gonzalez, E.M.; Bhattacharyya, S.; Jacobs, P.M.; et al. Dosimetry and first human experience with 89Zr-panitumumab. *Am. J. Nucl. Med. Mol. Imaging* 2017, 7, 195–203. [CrossRef]

46. Identifying NSCLC Patients Who Will Benefit from Afatinib Therapy Using [18F]Afatinib PET/CT. Available online: http://jnm.snmjournals.org/content/60/supplement_1/145 (accessed on 16 April 2020).

47. Velikyan, I.; Schweighöfer, P.; Feldwisch, J.; Seemann, J.; Frejd, F.Y.; Lindman, H.; Sörensen, J. Diagnostic HER2-binding radiopharmaceutical, [68Ga]Ga-ABY-025, for routine clinical use in breast cancer patients. *Am. J. Nucl. Med. Mol. Imaging* 2019, 9, 12–23. [PubMed]
48. Keyaerts, M.; Xavier, C.; Heemskerk, J.; Devoogdt, N.; Everaert, H.; Ackaert, C.; Vanhoeij, M.; Duhoux, F.P.; Gevaert, T.; Simon, P.; et al. Phase I study of 68Ga-HER2-Nanobody for PET/CT assessment of HER2 expression in breast carcinoma. *J. Nucl. Med.* 2016, 57, 27–33. [CrossRef] [PubMed]
49. Ulaner, G.A.; Hyman, D.M.; Ross, D.S.; Corben, A.; Chandraharapati, S.; Goldfarb, S.; McArthur, H.; Eriñjeri, J.P.; Keyaerts, M.; Xavier, C.; Heemskerk, J.; Devoogdt, N.; Everaert, H.; Ackaert, C.; Vanhoeij, M.; Duhoux, F.P.; et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT. *J. Nucl. Med.* 2016, 57, 1523–1528. [CrossRef] [PubMed]
50. Willemien Menke-Van Der Houven Van Oordt, C.; McGeoch, A.; Bergstrom, M.; Charalambidis, D.; Krenning, E.P.; et al. Improved estrogen receptor assessment by PET using the novel radiotracer 18 F-4FMFES in estrogen receptor–positive breast cancer patients: An ongoing phase II clinical trial. *J. Nucl. Med.* 2019, 60, 902–909. [CrossRef]
51. Lindner, T.; Loktev, A.; Giesel, F.; Kratochwil, C.; Altman, A.; Haberkorn, U. Targeting of activated fibroblasts for imaging and therapy. *Eur. J. Nucl. Med. Mol. Imaging* 2017, 43, 964–973. [CrossRef] [PubMed]
52. Baratto, L.; Duan, H.; Maecke, H.R.; Iagaru, A. Imaging the Distribution of Gastrin Releasing Peptide Receptors in Cancer. *J. Nucl. Med.* 2020. [CrossRef] [PubMed]
53. Paquette, M.; Lavallée, É.; Phoenix, S.; Ouellet, R.; Senta, H.; Van Lier, J.E.; Guérin, B.; Lecomte, R.; Turcotte, E.E. Improved estrogen receptor assessment by PET using the novel radiotracer 18 F-4FMFES in estrogen receptor–positive breast cancer patients: An ongoing phase II clinical trial. *J. Nucl. Med.* 2018, 59, 197–203. [CrossRef]
54. Lindner, T.; Loktev, A.; Giesel, F.; Kratochwil, C.; Altman, A.; Haberkorn, U. Targeting of activated fibroblasts for imaging and therapy. *Eur. J. Nucl. Med. Mol. Imaging* 2019, 60, 801–805. [CrossRef]
55. Loktev, A.; Lindner, T.; Burger, E.M.; Altman, A.; Giesel, F.; Kratochwil, C.; Debus, J.; Marmé, F.; Jäger, D.; Mier, W.; et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. *J. Nucl. Med.* 2019, 60, 1421–1429. [CrossRef] [PubMed]
56. Sørensen, M.; Frisch, K.; Bender, D.; Keiding, S. The potential use of 2-[18F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. *Eur. J. Nucl. Med. Mol. Imaging* 2011, 38, 1723–1731. [CrossRef] [PubMed]
57. Baratto, L.; Duan, H.; Maecke, H.R.; Iagaru, A. Imaging the Distribution of Gastrin Releasing Peptide Receptors in Cancer. *J. Nucl. Med.* 2020. [CrossRef] [PubMed]
58. Wieser, G.; Mansi, R.; Grosu, A.L.; Schultze-Seemann, W.; Dumont-Walter, R.A.; Meyer, P.T.; Maecke, H.R.; Kolb, H.; et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-trastuzumab PET/CT. *J. Nucl. Med.* 2016, 57, 1523–1528. [CrossRef] [PubMed]
59. Willemien Menke-Van Der Houven Van Oordt, C.; McGeoch, A.; Bergstrom, M.; Charalambidis, D.; Krenning, E.P.; et al. Improved estrogen receptor assessment by PET using the novel radiotracer 18 F-4FMFES in estrogen receptor–positive breast cancer patients: An ongoing phase II clinical trial. *J. Nucl. Med.* 2019, 60, 902–909. [CrossRef]
60. Minamimoto, R.; Sonni, I.; Hancock, S.; Vasanavala, S.; Loening, A.; Gambhir, S.S.; Iagaru, A. Prospective evaluation of 68 Ga-RM2 PET/MRI in patients with biochemical recurrence of prostate cancer and negative findings on conventional imaging. *J. Nucl. Med.* 2018, 59, 803–808. [CrossRef]
61. Maina, T.; Bergsma, H.; Kulkarni, H.R.; Mueller, D.; Charalambidis, D.; Krenning, E.P.; Nock, B.A.; De Jong, J.R.; Gietema, J.A.; Schröder, C.P.; Thomas, M.; et al. 89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors. *Eur. J. Nucl. Med. Mol. Imaging* 2016, 43, 964–973. [CrossRef]
62. Zhang, J.; Niu, G.; Fan, X.; Lang, L.; Hou, G.; Chen, L.; Wu, H.; Zhu, Z.; Li, F.; Chen, X. PET using a GRPR antagonist 68 Ga-RM26 in healthy volunteers and prostate cancer patients. *J. Nucl. Med.* 2019, 60, 902–909. [CrossRef]
63. Zhang, J.; Ni, G.; Fan, X.; Lang, L.; Hou, G.; Chen, L.; Wu, H.; Zhu, Z.; Li, F.; Chen, X. PET using a GRPR antagonist 68 Ga-RM26 in healthy volunteers and prostate cancer patients. *J. Nucl. Med.* 2019, 60, 902–909. [CrossRef]
65. Nock, B.A.; Kaloudi, A.; Lymeris, E.; Giarika, A.; Kulkarni, H.R.; Klette, I.; Singh, A.; Krenning, E.P.;
de Jong, M.; Maina, T.; et al. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide
Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results. J. Nucl. Med. 2017, 58, 75–80.
[CrossRef] [PubMed]
66. Luo, Y.; Pan, Q.; Yao, S.; Yu, M.; Wu, W.; Xue, H.; Kiesewetter, D.O.; Zhu, Z.; Li, F.; Zhao, Y.; et al. Glucagon-like
peptide-1 receptor PET/CT with 68Ga-NOTA-Exendin-4 for detecting localized insulinoma: A prospective
cohort study. J. Nucl. Med. 2016, 57, 715–720. [CrossRef] [PubMed]
67. Carrasquillo, J.A.; O’Donoghue, J.A.; Beylergil, V.; Ruan, S.; Pandit-Taskar, N.; Larson, S.M.; Smith-Jones, P.M.;
Lyashchenko, S.K.; Ohishi, N.; Ohtomo, T.; et al. I-124 codituzumab imaging and biodistribution in patients
with hepatocellular carcinoma. EJNMMI Res. 2018, 8, 1–11. [CrossRef]
68. Fleming, I.N.; Manavaki, R.; Blower, P.J.; West, C.; Williams, K.J.; Harris, A.L.; Domarkas, J.; Lord, S.;
Baldry, C.; Gilbert, F.J. Imaging tumour hypoxia with positron emission tomography. Br. J. Cancer 2015, 112,
238–250. [CrossRef] [PubMed]
69. Komar, G.; Seppänen, M.; Eskola, O.; Lindholm, P.; Grönroos, T.J.; Forsback, S.; Sipilä, H.; Evans, S.M.;
Solin, O.; Minn, H. 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer. J. Nucl. Med.
2008, 49, 1944–1951. [CrossRef]
70. Koh, W.J.; Rasey, J.S.; Evans, M.L.; Grierson, J.R.; Lewellen, T.K.; Graham, M.M.; Krohn, K.A.; Griffin, T.W.
Imaging of hypoxia in human tumors with [18F]fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys. 1992,
22, 199–212. [CrossRef]
71. Lewis, J.S.; Laforest, R.; Dephasashi, F.; Grigsby, P.W.; Welch, M.J.; Siegel, B.A. An imaging comparison of
64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J. Nucl. Med. 2008, 49, 1177–1182. [CrossRef]
72. Zegers, C.M.L.; van Elmpt, W.; Szardenings, K.; Kolb, H.; Waxman, A.; Subramaniam, R.M.; Moon, D.H.;
Brunetti, J.C.; Srinivas, S.M.; Lambin, P.; et al. Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial. Eur. J. Nucl. Med. Mol. Imaging 2015, 42,
1840–1849. [CrossRef]
73. Lewis, J.S.; Laforest, R.; Dephasashi, F.; Grigsby, P.W.; Welch, M.J.; Siegel, B.A. An imaging comparison of
64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J. Nucl. Med. 2008, 49, 1177–1182. [CrossRef]
74. 64Cu-LLP2A for Imaging Multiple Myeloma - Full Text View—ClinicalTrials.gov. Available online:
https://clinicaltrials.gov/ct2/show/NCT03804424 (accessed on 16 April 2020).
75. Chen, H.; Niu, G.; Wu, H.; Chen, X. Clinical application of radiolabeled RGD peptides for PET imaging of
integrin αvβ3. Theranostics 2016, 6, 78–92. [CrossRef]
76. Beer, A.J.; Haubner, R.; Wolf, I.; Goebel, M.; Luderscheidt, S.; Niemeyer, M.; Grosu, A.-L.; Martinez, M.-J.;
Wester, H.J.; Weber, W.A.; et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for
imaging alpha v beta3 expression. J. Nucl. Med. 2016, 57, 715–720. [CrossRef] [PubMed]
77. Lewis, J.S.; Laforest, R.; Dephasashi, F.; Grigsby, P.W.; Welch, M.J.; Siegel, B.A. An imaging comparison of
64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J. Nucl. Med. 2008, 49, 1177–1182. [CrossRef]
78. 64Cu-LLP2A for Imaging Multiple Myeloma - Full Text View—ClinicalTrials.gov. Available online:
https://clinicaltrials.gov/ct2/show/NCT03804424 (accessed on 16 April 2020).
79. Chen, H.; Niu, G.; Wu, H.; Chen, X. Clinical application of radiolabeled RGD peptides for PET imaging of
integrin αvβ3. Theranostics 2016, 6, 78–92. [CrossRef]
80. Beer, A.J.; Haubner, R.; Wolf, I.; Goebel, M.; Luderscheidt, S.; Niemeyer, M.; Grosu, A.-L.; Martinez, M.-J.;
Wester, H.J.; Weber, W.A.; et al. PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for
imaging alpha v beta3 expression. J. Nucl. Med. 2016, 57, 715–720. [CrossRef] [PubMed]
81. Chin, F.T.; Shen, B.; Liu, S.; Berganos, R.A.; Chang, E.; Mittra, E.; Chen, X.; Gambhir, S.S. First experience with
clinical-grade [ 18F]FPP (RGD) 2: An automated multi-step radiosynthesis for clinical PET studies. Mol.
Imaging Biol. 2012, 14, 88–95. [CrossRef]
82. Doss, M.; Kolb, H.C.; Zhang, J.J.; Belanger, M.J.; Stubbs, J.B.; Stabin, M.G.; Hostetler, E.D.; Alpaugh, R.K.;
Von Mehren, M.; Walsh, J.C.; et al. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5
determined from whole-body PET/CT in monkeys and humans. J. Nucl. Med. 2012, 53, 787–795. [CrossRef]
83. Mené, E.; Owennius, R.; Turkbey, B.; Sherry, R.; Bratslavsky, G.; Macholl, S.; Miller, M.P.; Somer, E.J.;
Lindenberg, L.; Adler, S.; et al. [18F]Fluciclatide in the in vivo evaluation of human melanoma and renal
tumors expressing αvβ3 and αvβ5 integrins. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 1879–1888. [CrossRef]
[PubMed]
84. Wan, W.; Guo, N.; Pan, D.; Yu, C.; Weng, Y.; Luo, S.; Ding, H.; Xu, Y.; Wang, L.; Lang, L.; et al. First experience of
18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J. Nucl. Med.
2013, 54, 691–698. [CrossRef] [PubMed]
85. Yu, C.; Pan, D.; Mi, B.; Xu, Y.; Lang, L.; Niu, G.; Yang, M.; Wan, W.; Chen, X. 18 F-Alfatide II PET/CT in
healthy human volunteers and patients with brain metastases. Eur. J. Nucl. Med. Mol. Imaging 2015, 42,
2021–2028. [CrossRef] [PubMed]
82. Zheng, K.; Liang, N.; Zhang, J.; Lang, L.; Zhang, W.; Li, S.; Zhao, J.; Niu, G.; Li, F.; Zhu, Z.; et al. 68Ga-NOTA-PRGD2 PET/CT for integrin imaging in patients with lung cancer. *J. Nucl. Med.* 2015, 56, 1823–1827. [CrossRef]
83. Lamberts, L.E.; Menke-Van Der Houven Van Oordt, C.W.; Ter Weele, E.J.; Bensch, F.; Smeenk, M.M.; Voortman, J.; Hoekstra, O.S.; Williams, S.P.; Fine, B.M.; Maslyar, D.; et al. ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody-drug conjugate treatment. *Clin. Cancer Res.* 2016, 22, 1642–1652. [CrossRef] [PubMed]
84. Violet, J.; Sandhu, S.; Iravani, A.; Ferdinandus, J.; Thang, S.P.; Kong, G.; Ravi Kumar, A.; Akhurst, T.; Schöder, H.M.; Dem et al. A Study of 18F-AlF-NOTA-Neurotensin PET/CT in patients with head and neck cancer. *J. Nucl. Med.* 2020, 60, 1587–1593. [CrossRef] [PubMed]
85. Czarniecki, M.; Mena, E.; Lindenberg, L.; Cačko, M.; Harmon, S.; Radtke, J.P.; Giesel, P.; Turkbey, B.; Choyke, P.L. Keeping up with the prostate-specific membrane antigens (PSMAs): An introduction to a new class of positron emission tomography (PET) imaging agents. *Transl. Androl. Urol.* 2018, 7, 831–843. [CrossRef]
86. Eiber, M.; Krönke, M.; Wurzer, A.; Ulbrich, L.; Jooß, L.; Maurer, T.; Horn, T.; Schiller, K.; Buschner, G.; et al. 18 F-rhPSMA-7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy. *J. Nucl. Med.* 2019. [CrossRef]
87. Lamberts, L.E.; Menke-Van Der Houven Van Oordt, C.W.; Ter Weele, E.J.; Bensch, F.; Smeenk, M.M.; Voortman, J.; Hoekstra, O.S.; Williams, S.P.; Fine, B.M.; Maslyar, D.; et al. ImmunoPET with anti-mesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody-drug conjugate treatment. *Clin. Cancer Res.* 2016, 22, 1642–1652. [CrossRef] [PubMed]
88. Hausner, S.H.; Bold, R.J.; Cheuy, L.Y.; Chew, H.K.; Daly, M.E.; Davis, R.A.; Foster, C.C.; Kim, E.J.; Sutcliffe, J.L. Preclinical development and first-in-human imaging of the integrin αvβ6 with [ 18 F]a v β 6 -binding peptide in metastatic carcinoma. *Clin. Cancer Res.* 2019, 25, 1206–1215. [CrossRef]
89. A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer - Full Text View - ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03516045 (accessed on 16 April 2020).
90. Picchio, M.; Castellucci, P. Clinical indications of 11C-choline PET/CT in prostate cancer patients with biochemical relapse. *Theranostics* 2012, 2, 313–317. [CrossRef] [PubMed]
91. Degrado, T.R.; Coleman, R.E.; Wang, S.; Baldwin, S.W.; Orr, M.D.; Robertson, C.N.; Polascik, T.J.; Price, D.T. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. *Cancer Res.* 2001, 61, 110–117.
92. Körlleck, L.; Bruchertseifer, F.; Kunikowska, J.; Kózari, H.; Körllick, B.; Jakuciritski, M.; Pawlak, D.; Apostolidis, C.; Mirzadeh, S.; et al. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue. *Eur. J. Nucl. Med. Mol. Imaging* 2018, 45, 1636–1644. [CrossRef] [PubMed]
93. Haberkorn, U. Identification of a novel ITGαβ6-binding peptide using protein separation and phage display. *Clin. Cancer Res.* 2017, 23, 4170–4180. [CrossRef]
94. Giesel, F.L.; Knorr, K.; Spohn, F.; Will, L.; Maurer, T.; Flechsig, F.; Neels, O.; Schiller, K.; Amaral, H.; Weber, W.A.; et al. Detection efficacy of 18 F-PSMA-1007 PET/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. *J. Nucl. Med.* 2019, 60, 1587–1593. [CrossRef]
95. Czarniecki, M.; Mena, E.; Lindenberg, L.; Cačko, M.; Harmon, S.; Radtke, J.P.; Giesel, P.; Turkbey, B.; Choyke, P.L. Keeping up with the prostate-specific membrane antigens (PSMAs): An introduction to a new class of positron emission tomography (PET) imaging agents. *Transl. Androl. Urol.* 2018, 7, 831–843. [CrossRef]
99. Bensch, F.; van der Veen, E.L.; Lub-de Hooge, M.N.; Jorritsma-Smit, A.; Boellaard, R.; Oosting, S.F.; Apostolou, G.P.; Schreiter, N.; Kaul, F.; Uiters, J.; Bouterfa, H.; Kaufmann, J.; Erlanger, T.E.; Cathomas, R.; et al. Optimized 124I PET dosimetry for prostate cancer using 89Zr-DFO-MSTP2109A anti-STEAP1 antibody. *Eur. J. Nucl. Med. Mol. Imaging* 2019, 46, 677–685. [CrossRef]

100. Jentzen, W.; Freudenberg, L.; Eising, E.G.; Sonnenschein, W.; Knust, J.; Bockisch, A. Optimized 124I PET dosimetry protocol for radiolabeled therapy of differentiated thyroid cancer. *J. Nucl. Med.* 2008, 49, 1017–1023. [CrossRef]

101. Ambrosini, V.; Campana, D.; Bodei, L.; Nanni, C.; Castellucci, P.; Allegri, V.; Montini, G.C.; Tomassetti, P.; Paganelli, G.; Fanti, S. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. *J. Nucl. Med.* 2010, 51, 669–673. [CrossRef]

102. Krebs, S.; Pandit-Taskar, N.; Reidy, D.; Beattie, B.J.; Lyashchenko, S.K.; Lewis, J.S.; Bodei, L.; Weber, W.A.; O’Donoghue, J.A. Biodistribution and radiation dose estimates for 68 Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. *Eur. J. Nucl. Med. Mol. Imaging* 2019, 46, 677–685. [CrossRef]

103. Shields, A.F.; Grierson, J.R.; Dohmen, B.M.; Machulla, H.J.; Stayanoff, J.C.; Lawhorn-Crews, J.M.; Obradovich, J.E.; Muzik, O.; Mangner, T.J. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. *Nat. Med.* 1998, 4, 1334–1336. [CrossRef]

104. Den Hollander, M.W.; Bensch, F.; Glaudemans, A.W.J.M.; Oude Munnink, T.H.; Enting, R.H.; Den Dunnen, W.F.A.; Heesters, M.A.A.M.; Kruyt, F.A.E.; Lub-De Hooge, M.N.; De Groot, J.C.; et al. TGF-β antibody uptake in recurrent high-grade glioma imaged with 89Zr-fresolimumab PET. *J. Nucl. Med.* 2015, 56, 1310–1314. [CrossRef]

105. Gaykema, S.B.M.; Schröder, C.P.; Vitfell-Rasmussen, J.; Chua, S.; Munnink, T.H.O.; Brouwers, A.H.; Bongaerts, A.H.H.; Akimov, M.; Fernandez-Ibarra, C.; Lub-De Hooge, M.N.; et al. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. *Clin. Cancer Res.* 2014, 20, 3945–3954. [CrossRef]

106. Bahce, I.; Huisman, M.C.; Verwer, E.E.; Ooijevaar, B.; Boutkourt, F.; Vugs, D.J.; van Dongen, G.A.M.S.; Boellaard, R.; Smit, E.F. Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer. *EJNMMI Res.* 2014, 4, 1–7. [CrossRef]

107. Van Asselt, S.J.; Oosting, S.F.; Brouwers, A.H.; Bongaerts, A.H.H.; De Jong, J.R.; Lub-De Hooge, M.N.; Oude Munnink, T.H.; Fiebrich, H.B.; Sluiter, W.J.; Links, T.P.; et al. Everolimus reduces 89Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors. *J. Nucl. Med.* 2014, 55, 1087–1092. [CrossRef]

108. Thorek, D.L.; Watson, P.A.; Lee, S.G.; Ku, A.T.; Bournazos, S.; Braun, K.; Kim, K.; Sjostrom, K.; Doran, M.G.; Lamminnaki, U.; et al. Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. *Sci. Transl. Med.* 2016, 8. [CrossRef]
136. Jansen, K.; Heirbaut, L.; Cheng, J.D.; Joossens, J.; Ryabtsova, O.; Cos, P.; Maes, L.; Lambeir, A.M.; De Meester, I.; Augustyns, K.; et al. Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinolyl)-glycyl-2-cyanopyrrolidine scaffold. *ACS Med. Chem. Lett.* 2013, 4, 491–496. [CrossRef]

137. Lindner, T.; Loktev, A.; Altmann, A.; Giesel, F.; Kratochwil, C.; Debus, J.; Jäger, D.; Mier, W.; Haberkorn, U. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. *J. Nucl. Med.* 2018, 59, 1415–1422. [CrossRef]

138. Goldenberg, D.M. Targeted therapy of cancer with radiolabeled antibodies. *J. Nucl. Med.* 2002, 43, 693–713.

139. Chiavenna, S.M.; Jaworski, J.P.; Vendrell, A. State of the art in anti-cancer mAbs. *J. Biomed. Sci.* 2017, 24, 15. [CrossRef]

140. Ghigna, C.; Valacca, C.; Biamonti, G. Alternative Splicing and Tumor Progression. *Curr. Genom.* 2008, 9, 556–570. [CrossRef]

141. Deri, M.A.; Zeglis, B.M.; Francesconi, L.C.; Lewis, J.S. PET imaging with 89Zr: From radiochemistry to the clinic. *Nucl. Med. Biol.* 2013, 40, 3–14. [CrossRef]

142. Jauw, Y.W.S.; Menke-van der Houven van Oordt, C.W.; Hoekstra, O.S.; Hendrikse, N.H.; Vugts, D.J.; Zijlstra, J.M.; Huisman, M.C.; van Dongen, G.A.M.S. Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? *Front. Pharmacol.* 2016, 7, 131. [CrossRef]

143. Verma, V.; Sprave, T.; Haque, W.; Simone, C.B.; Chang, J.Y.; Welsh, J.W.; Thomas, C.R. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. *J. Immunother. Cancer* 2018, 6, 128. [CrossRef]

144. Golebiowski, A.; Klopfenstein, S.R.; Portlock, D.E. Lead compounds discovered from libraries. *Drug Discov. Dev.* 2004, 7, 273–284. [CrossRef]

145. Comess, K.M.; Schurak, M.E. Affinity-based screening techniques for enhancing lead discovery. *Curr. Opin. Drug Discov. Dev.* 2004, 7, 411–416.

146. Keserü, G.M.; Makara, G.M. The influence of lead discovery strategies on the properties of drug candidates. *Nat. Rev. Drug Discov.* 2009, 8, 203–212. [CrossRef]

147. Davies, J.W.; Glick, M.; Jenkins, J.L. Streamlining lead discovery by aligning in silico and high-throughput screening. *Curr. Opin. Chem. Biol.* 2006, 10, 343–351. [CrossRef]

148. Shoichet, B.K.; McGovern, S.L.; Wei, B.; Irwin, J.J. Lead discovery using molecular docking. *Curr. Opin. Chem. Biol.* 2002, 6, 439–446. [CrossRef]

149. Liu, R.; Li, X.; Lam, K.S. Combinatorial chemistry in drug discovery. *Curr. Opin. Chem. Biol.* 2017, 38, 117–126. [CrossRef]

150. Kleiner, R.E.; Dumelin, C.E.; Liu, D.R. Small-molecule discovery from DNA-encoded chemical libraries. *Chem. Soc. Rev.* 2011, 40, 5707–5717. [CrossRef]

151. Yuen, L.H.; Franzini, R.M. Achievements, Challenges, and Opportunities in DNA-Encoded Library Research: An Academic Point of View. *ChemBioChem* 2017, 18, 829–836. [CrossRef]

152. Mannocci, L.; Leimbacher, M.; Wichert, M.; Scheuermann, J.; Neri, D. 20 years of DNA-encoded chemical libraries. *Chem. Commun.* 2011, 47, 12747–12753. [CrossRef]

153. Wichert, M.; Krall, N.; Decurtins, W.; Franzini, R.M.; Pretto, F.; Schneider, P.; Neri, D.; Scheuermann, J. Dual-display of small molecules enables the discovery of ligand pairs and facilitates affinity maturation. *Nat. Chem.* 2015, 7, 241–249. [CrossRef]

154. Blind, M.; Blank, M. Aptamer Selection Technology and Recent Advances. *Mol. Ther. - Nucleic Acids* 2015, 4, e223. [CrossRef]

155. Ladner, R.C.; Sato, A.K.; Gorzelany, J.; De Souza, M. Phage display-derived peptides as therapeutic alternatives to antibodies. *Drug Discov. Today* 2004, 9, 525–529. [CrossRef]

156. Shelat, A.A.; Guy, R.K. Scaffold composition and biological relevance of screening libraries. *Nat. Chem. Biol.* 2007, 3, 442–446. [CrossRef]

157. Binz, H.K.; Amstutz, P.; Kohl, A.; Stumpf, M.T.; Briand, C.; Forrer, P.; Grüter, M.G.; Plückthun, A. High-affinity binders selected from designed ankyrin repeat protein libraries. *Nat. Biotechnol.* 2004, 22, 575–582. [CrossRef]

158. Heinis, C.; Rutherford, T.; Freund, S.; Winter, G. Phage-encoded combinatorial chemical libraries based on bicyclic peptides. *Nat. Chem. Biol.* 2009, 5, 502–507. [CrossRef]
159. Murakami, H.; Ohta, A.; Ashigai, H.; Suga, H. A highly flexible tRNA acylation method for non-natural polypeptide synthesis. *Nat. Methods* 2006, 3, 357–359. [CrossRef]
160. Lam, K.S.; Salmon, S.E.; Hersh, E.M.; Hruby, V.J.; Kalmies, W.M.; Knapp, R.J. A new type of synthetic peptide library for identifying ligand-binding activity. *Nature* 1991, 354, 82–84. [CrossRef]
161. C. Martínez-Ceron, M.; L. Giudicessi, S.; L. Saavedra, S.; M. Gurevich-Messina, J.; Erra-Balsells, R.; Albérico, F.; Cascone, O.; A. Camperi. Latest Advances in OBOC Peptide Libraries. Improvements in Screening Strategies and Enlarging the Family From Linear to Cyclic Libraries. *Curr. Pharm. Biotechnol.* 2016, 17, 449–457. [CrossRef]
162. Song, A.; Zhang, J.; Lebrilla, C.B.; Lam, K.S. A novel and rapid encoding method based on mass spectrometry for “one-bead-one-compound” small molecule combinatorial libraries. *J. Am. Chem. Soc.* 2003, 125, 6180–6188. [CrossRef]
163. Peng, L.; Liu, R.; Marik, J.; Wang, X.; Takada, Y.; Lam, K.S. Combinatorial chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging. *Nat. Chem. Biol.* 2006, 2, 381–389. [CrossRef]
164. Dalm, S.U.; Bakker, I.L.; de Blois, E.; Doeswijk, G.N.; Konijnemberg, M.W.; Orlandi, F.; Barbato, D.; Tedesco, M.; Maina, T.; Nock, B.A.; et al. 68Ga/177 Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. *J. Nucl. Med.* 2017, 58, 293–299. [CrossRef]
165. Minn, I.; Koo, S.M.; Lee, H.S.; Brummet, M.; Rowe, S.P.; Gorin, M.A.; Sysa-Shah, P.; Lewis, W.D.; Ahn, H.-H.; Yang, X.; Minn, I.; Rowe, S.P.; Banerjee, S.R.; Gorin, M.A.; Brummet, M.; Lee, H.S.; Koo, S.M.; Sysa-Shah, P.; et al. 68Ga-XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. *Oncotarget* 2016, 7, 56471–56479. [CrossRef]
166. Komoriya, A.; Green, L.J.; Mervic, M.; Yamada, S.S.; Yamada, K.M.; Humphries, M.J. The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. *J. Biol. Chem.* 1991, 266, 15075–15079.
167. Lin, K.C.; Ateeq, H.S.; Hsiung, S.H.; Chong, L.T.; Zimmerman, C.N.; Castro, A.; Lee, W.C.; Hammond, C.E.; Kalkunte, S.; Chen, L.L.; et al. Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses. *J. Med. Chem.* 1999, 42, 920–934. [CrossRef]
168. Beaino, W.; Anderson, C.J. PET imaging of very late antigen-4 in melanoma: Comparison of 68Ga- and 64Cu-Labeled NODAGA and CB-TE1A1P-LLP2A conjugates. *J. Nucl. Med.* 2014, 55, 1856–1863. [CrossRef] [PubMed]
169. Yang, X.; Minn, I.; Rowe, S.P.; Banerjee, S.R.; Gorin, M.A.; Brummet, M.; Lee, H.S.; Koo, S.M.; Sysa-Shah, P.; Mease, R.C.; et al. Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor. *Oncotarget* 2015, 6, 33733–33742. [CrossRef]
170. Mindt, T.L.; Pike, V.W.; et al. Consensus nomenclature rules for radiopharmaceutical chemistry—Setting the record straight. *Nucl. Med. Biol.* 2013, 40, 245–251. [CrossRef] [PubMed]
171. Lapi, S.E.; Welch, M.J. A historical perspective on the specific activity of radiopharmaceuticals: What have we learned in the 35 years of the ISRC? *Nucl. Med. Biol.* 2012, 39, 601–608. [CrossRef]
172. Conti, M.; Eriksson, L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. *EJNMMI Phys.* 2016, 3, 8. [CrossRef]
173. Sergeev, M.; Lazari, M.; Morgia, F.; Collins, J.; Javed, M.R.; Sergeeva, O.; Jones, J.; Phelps, M.E.; Lee, J.T.; Keng, P.Y.; et al. Performing radiosynthesis in microvolumes to maximize molar activity of tracers for positron emission tomography. *Commun. Chem.* 2018, 1, 1–10. [CrossRef]
174. Coenen, H.H.; Gee, A.D.; Adam, M.; Antoni, G.; Cutler, C.S.; Fujibayashi, Y.; Jeong, J.M.; Mach, R.H.; Mindt, T.L.; Pike, V.W.; et al. Consensus nomenclature rules for radiopharmaceutical chemistry—Setting the record straight. *Nucl. Med. Biol.* 2017, 55, v–xi. [CrossRef]
175. Jacobson, O.; Chen, X.; Weiss, I.D.; Kiesewetter, D.O.; Farber, J.M. PET of Tumor CXCR4 Expression with 4-18F-T140. *J. Nucl. Med.* 2010, 51, 1796–1804. [CrossRef]
176. Sergeev, M.; Lazari, M.; Morgia, F.; Collins, J.; Javed, M.R.; Sergeeva, O.; Jones, J.; Phelps, M.E.; Lee, J.T.; Keng, P.Y.; et al. Performing radiosynthesis in microvolumes to maximize molar activity of tracers for positron emission tomography. *Commun. Chem.* 2018, 1, 1–10. [CrossRef]
177. Coenen, H.H.; Gee, A.D.; Adam, M.; Antoni, G.; Cutler, C.S.; Fujibayashi, Y.; Jeong, J.M.; Mach, R.H.; Mindt, T.L.; Pike, V.W.; et al. Consensus nomenclature rules for radiopharmaceutical chemistry—Setting the record straight. *Nucl. Med. Biol.* 2017, 55, v–xi. [CrossRef]
178. Nonnekens, J.; Schottelius, M. “Luke! Luke! Don’t! It’s a trap!”—spotlight on bias in animal experiments in nuclear oncology. *Eur. J. Nucl. Med. Mol. Imaging* 2020, 47, 1024–1026. [CrossRef]

179. Saha, G.B. Production of Radionuclides. In *Physics and Radiobiology of Nuclear Medicine*; Springer: New York, NY, USA, 2006; pp. 44–55.

180. Synowiecki, M.A.; Perk, L.R.; Nijsen, J.F.W. Production of novel diagnostic radionuclides in small medical cyclotrons. *EJNMMI Radiopharm. Chem.* 2018, 3. [CrossRef]

181. Holland, J.P.; Williamson, M.J.; Lewis, J.S. Unconventional Nuclides for Radiopharmaceuticals. *Mol. Imaging* 2010, 9, 1–20. [CrossRef]

182. Yuan, Z.; Nodwell, M.B.; Yang, H.; Malik, N.; Merkens, H.; Bernard-Gauthier, V.; Schirrmacher, R.; Coursey, J.S.; Zucker, M.A.; Chang, J. Stopping-Power & Range Tables for Electrons, Protons, and Helium Ions. *NISTIR* 2017, 4999, 1–17. [CrossRef]

183. Yang, L.; Scott, P.J.H.; Shao, X. [11C]Carbon Dioxide: Starting Point for Labeling PET Radiopharmaceuticals. *Chem. Rev.* 2012, 116, 719–766. [CrossRef]

184. Andersson, J.; Truong, P.; Halldin, C. In-target produced [11C]methane: Increased specific radioactivity. *Appl. Radiat. Isot.* 2009, 67, 106–110. [CrossRef]

185. Deng, X.; Rong, J.; Wang, L.; Vasdev, N.; Zhang, L.; Josephson, L.; Liang, S.H. Chemistry for Positron Emission Tomography: Recent Advances in 11 C-, 18 F-, 13 N-, and 15 O-Labeling Reactions. *Angew. Chemie - Int. Ed.* 2019, 58, 2580–2605. [CrossRef]

186. Dahl, K.; Halldin, C.; Schou, M. New methodologies for the preparation of carbon-11 labeled radiopharmaceuticals. *Clin. Transl. Imaging* 2017, 5, 275–289. [CrossRef]

187. Teare, H.; Robins, E.G.; Árstad, E.; Luthra, S.K.; Bernard-Gauthier, V.; Schirrmacher, R.; Coursey, J.S.; Zucker, M.A.; Chang, J. Radiosynthesis and Evaluation of [18F]Selectfluor bis(triflate). *Angew. Chemie Int. Ed.* 2010, 49, 6821–6824. [CrossRef] [PubMed]

188. Larsen, P.; Ulin, J.; Dahlstrøm, K.; Jensen, M. Synthesis of [11C]iodomethane by iodination of [11C]methane. *Appl. Radiat. Isot.* 1997, 48, 153–157. [CrossRef]

189. Fani, M.; Maecke, H.R.; Okarvi, S.M. Radiolabeled peptides: Valuable tools for the detection and treatment of cancer. *Theranostics* 2012, 2, 481–501. [CrossRef] [PubMed]

190. Nonnekens, J.; Schottelius, M. “Luke! Luke! Don’t! It’s a trap!”—spotlight on bias in animal experiments in nuclear oncology. *Eur. J. Nucl. Med. Mol. Imaging* 2020, 47, 1024–1026. [CrossRef]

191. Synowiecki, M.A.; Perk, L.R.; Nijsen, J.F.W. Production of novel diagnostic radionuclides in small medical cyclotrons. *EJNMMI Radiopharm. Chem.* 2018, 3. [CrossRef]

192. Holland, J.P.; Williamson, M.J.; Lewis, J.S. Unconventional Nuclides for Radiopharmaceuticals. *Mol. Imaging* 2010, 9, 1–20. [CrossRef]

193. Yuan, Z.; Nodwell, M.B.; Yang, H.; Malik, N.; Merkens, H.; Bernard-Gauthier, V.; Bailey, J.J.; Liu, Z.; Wängler, B.; Wängler, C.; Jurkschat, K.; Perrin, D.M.; Schirrmacher, R. From Unorthodox to Established: The Current Status of 18F-Trifluoroborate- and 18F-SiFA-Based Radiopharmaceuticals in PET Nuclear Imaging. *Angew. Chemie Int. Ed.* 2012, 51, 2330–2332. [CrossRef] [PubMed]

194. Larsen, P.; Ulin, J.; Dahlstrøm, K.; Jensen, M. Synthesis of [11C]iodomethane by iodination of [11C]methane. *Appl. Radiat. Isot.* 1997, 48, 153–157. [CrossRef]

195. Wang, G.B. Production of Radionuclides. In *Physics and Radiobiology of Nuclear Medicine*; Springer: New York, NY, USA, 2006; pp. 44–55.

196. Gouverneur, V. Radiochemistry: Flipping fluoride’s reactivity. *Nat. Chem.* 2012, 4, 152–154. [CrossRef] [PubMed]

197. Dahl, K.; Halldin, C.; Schou, M. New methodologies for the preparation of carbon-11 labeled radiopharmaceuticals. *Clin. Transl. Imaging* 2017, 5, 275–289. [CrossRef]

198. pillow, A.A.; Dannals, R.F.; Ravert, H.T.; Wagner, H.N. Reductive amination of [18F]fluorobenzaldehydes: Radiosyntheses of [2-18F]- and [4-18F]fluorodexetimides. *J. Label. Compd. Radiopharm.* 1990, 28, 1189–1199. [CrossRef]

199. Nonnekens, J.; Schottelius, M. “Luke! Luke! Don’t! It’s a trap!”—spotlight on bias in animal experiments in nuclear oncology. *Eur. J. Nucl. Med. Mol. Imaging* 2020, 47, 1024–1026. [CrossRef]

200. Fani, M.; Maecke, H.R.; Okarvi, S.M. Radiolabeled peptides: Valuable tools for the detection and treatment of cancer. *Theranostics* 2012, 2, 481–501. [CrossRef] [PubMed]
201. Roxin, Á.; Zhang, C.; Huh, S.; Lepage, M.; Zhang, Z.; Lin, K.S.; Bénard, F.; Perrin, D.M. A Metal-Free DOTA-Conjugated 18F-Labeled Radiotracer: [18F]DOTA-AMBF3-LLP2A for Imaging VLA-4 Over-Expression in Murine Melanoma with Improved Tumor Uptake and Greatly Enhanced Renal Clearance. *Bioconjug. Chem.* **2019**, *30*, 1210–1219. [CrossRef] [PubMed]

202. Lepage, M.L.; Kuo, H.T.; Roxin, Á.; Huh, S.; Zhang, Z.; Kandasamy, R.; Merkens, H.; Kumlin, J.O.; Limoges, A.; Zeisler, S.K.; et al. Toward 18F-Labeled Theranostics: A Single Agent that Can Be Labeled with 18F, 64Cu, or 177Lu. *ChemBioChem* **2020**, *21*, 943–947. [CrossRef]

203. Vallabhajosula, S. Quality Control of PET Radiopharmaceuticals. In *Molecular Imaging*; Springer: Berlin/Heidelberg, Germany, 2009; pp. 197–204.

204. Huang, Y.-Y. An Overview of PET Radiopharmaceuticals in Clinical Use: Regulatory, Quality and Pharmacopeia Monographs of the United States and Europe. In *Nuclear Medicine Physics*; IntechOpen: London, UK, 2019.

205. Bigott-Hennkens, H.M.; Dannoon, S.; Lewis, M.R.; Jurisson, S. In vitro receptor binding assays: General methods and considerations. *Q. J. Nucl. Med. Mol. Imaging* **2008**, *52*, 245–253.

206. Hulme, E.C.; Trevethick, M.A. Ligand binding assays at equilibrium: Validation and interpretation. *Br. J. Pharmacol.* **2010**, *161*, 1219–1237. [CrossRef]

207. Tang, Y.; Zeng, X.; Liang, J. Surface plasmon resonance: An introduction to a surface spectroscopy technique. *J. Chem. Educ.* **2010**, *87*, 742–746. [CrossRef]

208. Kumaraswamy, S.; Tobias, R. Label-free kinetic analysis of an antibody-antigen interaction using biolayer interferometry. In *Protein-Protein Interactions: Methods and Applications: Second Edition*; Springer: New York, NY, USA, 2015; Volume 1278, ISBN 9781493924257.

209. Duff, M.R.; Grubbs, J.; Howell, E.E. Isothermal titration calorimetry for measuring macromolecule-ligand affinity. *J. Vis. Exp.* 2011. [CrossRef]

210. Wienken, C.J.; Baaske, P.; Rothbauer, U.; Braun, D.; Duhr, S. Protein-binding assays in biological liquids using microscale thermophoresis. *Nat. Commun.* **2010**, *1*, 1–7. [CrossRef] [PubMed]

211. Reddy, S.; Robinson, M.K. Immuno-Positron Emission Tomography in Cancer Models. *Semin. Nucl. Med.* **2010**, *40*, 182–189. [CrossRef]

212. Anderson, C.J.; Ferdani, R. Copper-64 radiopharmaceuticals for PET imaging of cancer: Advances in preclinical and clinical research. *Cancer Biother. Radiopharm.* **2009**, *24*, 379–393. [CrossRef] [PubMed]

213. Mansour, N.; Paquette, M.; Ait-Mohand, S.; Dumulon-Perreault, V.; Guérin, B. Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [64Cu]-DOTHA2-PEG-RM26. *Nucl. Med. Biol.* **2018**, *56*, 31–38. [CrossRef] [PubMed]

214. Zhang, D.; Luo, G.; Ding, X.; Lu, C. Preclinical experimental models of drug metabolism and disposition in drug discovery and development. *Acta Pharm. Sin. B* **2012**, *2*, 549–561. [CrossRef]

215. Nock, B.A.; Maina, T.; Krening, E.P.; de Jong, M. “To Serve and Protect”: Enzyme Inhibitors as Radiopeptide Escorts Promote Tumor Targeting. *J. Nucl. Med.* **2014**, *55*, 121–127. [CrossRef] [PubMed]

216. Lin, K.S.; Pan, J.; Amouroux, G.; Turashvili, G.; Mesak, F.; Hundal-Jabal, N.; Pourghiasian, M.; Lau, J.; Jenni, S.; Aparicio, S.; et al. In vivo radioimaging of bradykinin receptor B1, a widely overexpressed molecule in human cancer. *Cancer Res.* **2015**, *75*, 387–393. [CrossRef] [PubMed]

217. Lever, S.Z.; Fan, K.H.; Lever, J.R. Tactics for preclinical validation of receptor-binding radiotracers. *Nucl. Med. Biol.* **2017**, *44*, 4–30. [CrossRef] [PubMed]

218. Liu, Z.; Chen, X. Simple bioconjugate chemistry serves great clinical advances: Albumin as a versatile platform for diagnosis and precision therapy. *Chem. Soc. Rev.* **2016**, *45*, 1432–1456. [CrossRef] [PubMed]

219. Müller, C.; Farkas, R.; Borgna, F.; Schmid, R.M.; Benešová, M.; Schibli, R. Synthesis, Radiolabeling, and Characterization of Plasma Protein-Binding Ligands: Potential Tools for Modulation of the Pharmacokinetic Properties of (Radio)Pharmaceuticals. *Bioconjug. Chem.* **2017**, *28*, 2372–2383. [CrossRef]

220. Amini, N.; Nakao, R.; Schou, M.; Halldin, C. Determination of plasma protein binding of positron emission tomography radioligands by high-performance frontal analysis. *J. Pharm. Biomed. Anal.* **2014**, *98*, 1401–1443. [CrossRef]

221. Lindmo, T.; Boven, E.; Cuttitta, F.; Fedorko, J.; Bunn, P.A. Determination of the immunoreactive function of radionabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. *J. Immunol. Methods* **1984**, *72*, 77–89. [CrossRef]
222. Sharma, S.K.; Lyashchenko, S.K.; Park, H.A.; Pillarsetty, N.; Roux, Y.; Wu, J.; Poty, S.; Tully, K.M.; Poirier, J.T.; Lewis, J.S. A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals. *Nucl. Med. Biol.* 2019, 71, 32–38. [CrossRef] [PubMed]

223. Lamberts, D. Drugs and receptors. *Contin. Educ. Anaesth. Crit. Care Pain* 2004, 4, 181–184. [CrossRef]

224. Xiao, S.-H.; Reagan, J.; Lee, P.; Fu, A.; Schwandner, R.; Zhao, X.; Knop, J.; Beckmann, H.; Young, S. High Throughput Screening for Orphan and Liganded GPCRs. *Comb. Chem. High Throughput Screen.* 2008, 11, 195–215. [CrossRef] [PubMed]

225. Chatziioannou, A.F. Molecular imaging of small animals with dedicated PET tomographs. *Eur. J. Nucl. Med.* 2002, 29, 98–114. [CrossRef] [PubMed]

226. Hutchins, G.D.; Miller, M.A.; Soon, V.C.; Receveur, T. Small animal PET imaging. *ILAR J.* 2008, 49, 54–65. [CrossRef]

227. Zhang, C.; Zhang, Z.; Merkens, H.; Zeisler, J.; Colpo, N.; Hundal-Jabal, N.; Perrin, D.M.; Lin, K.S.; Bénard, F. 18F-Labeled Cyclized α-Melanocyte-Stimulating Hormone Derivatives for Imaging Human Melanoma Xenograft with Positron Emission Tomography. *Sci. Rep.* 2019, 9. [CrossRef]

228. Fueger, B.J.; Czernin, J.; Hildebrandt, I.; Tran, C.; Halpern, B.S.; Stout, D.; Phelps, M.E.; Weber, W.A. Impact of animal handling on the results of 18F-FDG PET studies in mice. *J. Nucl. Med.* 2006, 47, 999–1006.

229. Soret, M.; Bacharach, S.L.; Buvat, I. Partial-volume effect in PET tumor imaging. *J. Nucl. Med.* 2007, 48, 932–945. [CrossRef]

230. Hildebrandt, I.J.; Su, H.; Weber, W.A. Anesthesia and other considerations for in vivo imaging of small animals. *ILAR J.* 2008, 49, 17–26. [CrossRef]

231. Heneweer, C.; Holland, J.P.; Divilov, V.; Carlin, S.; Lewis, J.S. Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. *J. Nucl. Med.* 2011, 52, 625–633. [CrossRef]

232. Siegel, J.A.; Thomas, S.R.; Stubbs, J.B.; Stabin, M.G.; Hays, M.T.; Koral, K.F.; Robertson, J.S.; Howell, R.W.; Wessels, B.W.; Fisher, D.R.; et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. *J. Nucl. Med.* 1999, 40, 375–615. [PubMed]

233. Bolch, W.E.; Eckerman, K.F.; Sgouros, G.; Thomas, S.R.; Brill, A.B.; Fisher, D.R.; Howell, R.W.; Meredith, R.; Wessels, B.W. MIRD pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. *J. Nucl. Med.* 2009, 50, 477–484. [CrossRef]

234. Sparks, R.; Aydogan, B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. *Sixth Int. Radiophys. Dosim. Symp.* 1999, 705–716.

235. Lu, S.; Haskali, M.B.; Ruley, K.M.; Dreyfus, N.J.-F.; DuBois, S.L.; Paul, S.; Liow, J.-S.; Morse, C.L.; Savings, A.; et al. PET ligands [18F]LSN3316612 and [11C]LSN3316612 quantify O-linked-β-N-acetyl-glucosamine hydrolase in the brain. *Sci. Transl. Med.* 2020, 12, eaau2939. [CrossRef] [PubMed]

236. FDA ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Q&A. *Guideline* 2013, 14, 84–86. [CrossRef]

237. U.S. Department of Health and Human Services- Food and Drug Administration; Center for Drug Evaluation and Research (CDER) Microdose Radiopharmaceutical Diagnostic Drugs. Nonclinical Study Recommendations Guidance for Industry. *Guideline* 2018, 1–4.

238. European Medicines Agency Guideline on the non-clinical requirements for radiopharmaceuticals. *Guideline* 2018, 44, 1–10.

239. Silva-Lima, B.; Carlson, D.; Jones, D.R.; Laurie, D.; Stahl, E.; Maria, V.; Janssens, W.; Robinson, W.T. The European and American use of exploratory approaches for first-in-human studies. *Clin. Transl. Sci.* 2010, 3, 38–41. [CrossRef]

240. FDA Guidance for industry, investigators, and reviewers: Exploratory IND studies. *Guideline* 2006, 25, 167–174. [CrossRef]

241. Nimmagadda, S.; Shelake, S.; Pomper, M.G. Preclinical Experimentation in Oncology. In *Radiopharmaceutical Chemistry*, Springer International Publishing: Cham, Switzerland, 2019; pp. 569–582.